WO2012093388A2 - Biologic sunscreen compositions - Google Patents
Biologic sunscreen compositions Download PDFInfo
- Publication number
- WO2012093388A2 WO2012093388A2 PCT/IL2011/000974 IL2011000974W WO2012093388A2 WO 2012093388 A2 WO2012093388 A2 WO 2012093388A2 IL 2011000974 W IL2011000974 W IL 2011000974W WO 2012093388 A2 WO2012093388 A2 WO 2012093388A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- skin
- whole cell
- algae
- cell algae
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 192
- 230000000475 sunscreen effect Effects 0.000 title description 39
- 239000000516 sunscreening agent Substances 0.000 title description 39
- 241000195493 Cryptophyta Species 0.000 claims abstract description 103
- 238000000034 method Methods 0.000 claims abstract description 45
- 230000000699 topical effect Effects 0.000 claims abstract description 38
- 230000037072 sun protection Effects 0.000 claims abstract description 26
- 239000002537 cosmetic Substances 0.000 claims description 25
- 230000009759 skin aging Effects 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 12
- 230000032683 aging Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 210000003491 skin Anatomy 0.000 description 80
- 238000009472 formulation Methods 0.000 description 47
- 239000003795 chemical substances by application Substances 0.000 description 36
- -1 serum Substances 0.000 description 31
- 206010040954 Skin wrinkling Diseases 0.000 description 20
- 239000004615 ingredient Substances 0.000 description 18
- 241000196321 Tetraselmis Species 0.000 description 15
- 230000005855 radiation Effects 0.000 description 14
- 239000006210 lotion Substances 0.000 description 12
- 230000037303 wrinkles Effects 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 241000224474 Nannochloropsis Species 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 238000002834 transmittance Methods 0.000 description 9
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 8
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 8
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 8
- 230000005540 biological transmission Effects 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000004599 antimicrobial Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 239000003349 gelling agent Substances 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000007762 w/o emulsion Substances 0.000 description 5
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 4
- 229920002498 Beta-glucan Polymers 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 235000011399 aloe vera Nutrition 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000005515 coenzyme Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000003974 emollient agent Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000003906 humectant Substances 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000000116 mitigating effect Effects 0.000 description 4
- 239000002077 nanosphere Substances 0.000 description 4
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 4
- 229960001679 octinoxate Drugs 0.000 description 4
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 4
- 229960000601 octocrylene Drugs 0.000 description 4
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 3
- 235000002961 Aloe barbadensis Nutrition 0.000 description 3
- 244000144927 Aloe barbadensis Species 0.000 description 3
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 3
- 108010087806 Carnosine Proteins 0.000 description 3
- 241000723346 Cinnamomum camphora Species 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 3
- 241000220317 Rosa Species 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 239000003212 astringent agent Substances 0.000 description 3
- 229960005193 avobenzone Drugs 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 229960000846 camphor Drugs 0.000 description 3
- 229930008380 camphor Natural products 0.000 description 3
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 3
- 229940044199 carnosine Drugs 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229940106189 ceramide Drugs 0.000 description 3
- 150000001783 ceramides Chemical class 0.000 description 3
- 229920002770 condensed tannin Polymers 0.000 description 3
- 235000012754 curcumin Nutrition 0.000 description 3
- 239000004148 curcumin Substances 0.000 description 3
- 229940109262 curcumin Drugs 0.000 description 3
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229960004705 kojic acid Drugs 0.000 description 3
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 150000002632 lipids Chemical group 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 239000002078 nanoshell Substances 0.000 description 3
- 229940101267 panthenol Drugs 0.000 description 3
- 235000020957 pantothenol Nutrition 0.000 description 3
- 239000011619 pantothenol Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 229960003742 phenol Drugs 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 235000020944 retinol Nutrition 0.000 description 3
- 229960003471 retinol Drugs 0.000 description 3
- 239000011607 retinol Substances 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 230000037075 skin appearance Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 2
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 description 2
- OMWSZDODENFLSV-UHFFFAOYSA-N (5-chloro-2-hydroxyphenyl)-phenylmethanone Chemical compound OC1=CC=C(Cl)C=C1C(=O)C1=CC=CC=C1 OMWSZDODENFLSV-UHFFFAOYSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 2
- FIDRAVVQGKNYQK-UHFFFAOYSA-N 1,2,3,4-tetrahydrotriazine Chemical compound C1NNNC=C1 FIDRAVVQGKNYQK-UHFFFAOYSA-N 0.000 description 2
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 2
- ZXDDPOHVAMWLBH-UHFFFAOYSA-N 2,4-Dihydroxybenzophenone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=CC=C1 ZXDDPOHVAMWLBH-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- 240000001432 Calendula officinalis Species 0.000 description 2
- 235000005881 Calendula officinalis Nutrition 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 241000192700 Cyanobacteria Species 0.000 description 2
- 244000133098 Echinacea angustifolia Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001501885 Isochrysis Species 0.000 description 2
- FAIXYKHYOGVFKA-UHFFFAOYSA-N Kinetin Natural products N=1C=NC=2N=CNC=2C=1N(C)C1=CC=CO1 FAIXYKHYOGVFKA-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 229940124761 MMP inhibitor Drugs 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010040799 Skin atrophy Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- HEAHZSUCFKFERC-IWGRKNQJSA-N [(2e)-2-[[4-[(e)-[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanylidene]methyl]phenyl]methylidene]-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C\C(C=C1)=CC=C1\C=C/1C(=O)C2(CS(O)(=O)=O)CCC\1C2(C)C HEAHZSUCFKFERC-IWGRKNQJSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229920006243 acrylic copolymer Polymers 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 229960002255 azelaic acid Drugs 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 2
- 150000008366 benzophenones Chemical class 0.000 description 2
- 150000001277 beta hydroxy acids Chemical class 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- WXNRYSGJLQFHBR-UHFFFAOYSA-N bis(2,4-dihydroxyphenyl)methanone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=C(O)C=C1O WXNRYSGJLQFHBR-UHFFFAOYSA-N 0.000 description 2
- 229940036350 bisabolol Drugs 0.000 description 2
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000014134 echinacea Nutrition 0.000 description 2
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940068171 ethyl hexyl salicylate Drugs 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 229960002598 fumaric acid Drugs 0.000 description 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 2
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229960002733 gamolenic acid Drugs 0.000 description 2
- 229940105040 geranium extract Drugs 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 239000013003 healing agent Substances 0.000 description 2
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 2
- 229940091173 hydantoin Drugs 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229960002163 hydrogen peroxide Drugs 0.000 description 2
- VAMFXQBUQXONLZ-UHFFFAOYSA-N icos-1-ene Chemical compound CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- QANMHLXAZMSUEX-UHFFFAOYSA-N kinetin Chemical compound N=1C=NC=2N=CNC=2C=1NCC1=CC=CO1 QANMHLXAZMSUEX-UHFFFAOYSA-N 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- QUAMTGJKVDWJEQ-UHFFFAOYSA-N octabenzone Chemical compound OC1=CC(OCCCCCCCC)=CC=C1C(=O)C1=CC=CC=C1 QUAMTGJKVDWJEQ-UHFFFAOYSA-N 0.000 description 2
- 229960001173 oxybenzone Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 229940067631 phospholipid Drugs 0.000 description 2
- 235000018192 pine bark supplement Nutrition 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940106796 pycnogenol Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229960001755 resorcinol Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 229930003802 tocotrienol Natural products 0.000 description 2
- 239000011731 tocotrienol Substances 0.000 description 2
- 229940068778 tocotrienols Drugs 0.000 description 2
- 235000019148 tocotrienols Nutrition 0.000 description 2
- 229940100617 topical lotion Drugs 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 229960003500 triclosan Drugs 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- HEOCBCNFKCOKBX-RELGSGGGSA-N (1s,2e,4r)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)[C@]2(C)CC[C@H]\1C2(C)C HEOCBCNFKCOKBX-RELGSGGGSA-N 0.000 description 1
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
- YHHHHJCAVQSFMJ-FNORWQNLSA-N (3e)-deca-1,3-diene Chemical compound CCCCCC\C=C\C=C YHHHHJCAVQSFMJ-FNORWQNLSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 1
- 150000000182 1,3,5-triazines Chemical class 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- ZIMOURYOOIPWBS-UHFFFAOYSA-N 2-(1-benzofuran-2-yl)-1h-indole Chemical class C1=CC=C2OC(C3=CC4=CC=CC=C4N3)=CC2=C1 ZIMOURYOOIPWBS-UHFFFAOYSA-N 0.000 description 1
- SEYCAKMZVYADRS-UHFFFAOYSA-N 2-(3-butylisoquinolin-1-yl)oxyethyl-dimethylazanium;chloride Chemical compound [Cl-].C1=CC=C2C(OCC[NH+](C)C)=NC(CCCC)=CC2=C1 SEYCAKMZVYADRS-UHFFFAOYSA-N 0.000 description 1
- 229920000536 2-Acrylamido-2-methylpropane sulfonic acid Polymers 0.000 description 1
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 description 1
- FSSICIQKZGUEAE-UHFFFAOYSA-N 2-[benzyl(pyridin-2-yl)amino]ethyl-dimethylazanium;chloride Chemical compound Cl.C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 FSSICIQKZGUEAE-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- OTYVBQZXUNBRTK-UHFFFAOYSA-N 3,3,6-trimethylhepta-1,5-dien-4-one Chemical compound CC(C)=CC(=O)C(C)(C)C=C OTYVBQZXUNBRTK-UHFFFAOYSA-N 0.000 description 1
- NJLKZOZYTRRDBO-UHFFFAOYSA-N 3-iodopropyl n-butylcarbamate Chemical compound CCCCNC(=O)OCCCI NJLKZOZYTRRDBO-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical class NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- IRLPACMLTUPBCL-KQYNXXCUSA-N 5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](O)[C@H]1O IRLPACMLTUPBCL-KQYNXXCUSA-N 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical class OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 240000006054 Agastache cana Species 0.000 description 1
- 235000006667 Aleurites moluccana Nutrition 0.000 description 1
- 244000136475 Aleurites moluccana Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 235000012871 Arctostaphylos uva ursi Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000285470 Artemesia Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241001147674 Chlorarachniophyceae Species 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- QCZAWDGAVJMPTA-RNFRBKRXSA-N ClC1=CC=CC(=N1)C1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C Chemical compound ClC1=CC=CC(=N1)C1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C QCZAWDGAVJMPTA-RNFRBKRXSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- 241000199914 Dinophyceae Species 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 241000195623 Euglenida Species 0.000 description 1
- 239000001293 FEMA 3089 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241001517276 Glaucocystophyceae Species 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- 241000206759 Haptophyceae Species 0.000 description 1
- 102100034629 Hemopexin Human genes 0.000 description 1
- 108010026027 Hemopexin Proteins 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- 229940124790 IL-6 inhibitor Drugs 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- ZRVSAJIGCDWADZ-UHFFFAOYSA-N Leucoanthocyanin Natural products OCC1OC(CC(O)C1O)OC2C(O)c3c(O)cc(O)cc3OC2c4ccc(O)c(O)c4 ZRVSAJIGCDWADZ-UHFFFAOYSA-N 0.000 description 1
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 241000196305 Nannochloris Species 0.000 description 1
- 241001250129 Nannochloropsis gaditana Species 0.000 description 1
- 241000517188 Nannochloropsis limnetica Species 0.000 description 1
- 241000224476 Nannochloropsis salina Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 241001127637 Plantago Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000206618 Porphyridium Species 0.000 description 1
- 229940127343 Potassium Channel Agonists Drugs 0.000 description 1
- SYCBXBCPLUFJID-UHFFFAOYSA-N Pramoxine hydrochloride Chemical compound Cl.C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 SYCBXBCPLUFJID-UHFFFAOYSA-N 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
- 102000000471 Prostaglandin F receptors Human genes 0.000 description 1
- 108050008995 Prostaglandin F receptors Proteins 0.000 description 1
- 229940127473 Prostaglandin Receptor Agonists Drugs 0.000 description 1
- 229940122144 Prostaglandin receptor antagonist Drugs 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 235000009413 Ratibida columnifera Nutrition 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 240000006661 Serenoa repens Species 0.000 description 1
- 235000005318 Serenoa repens Nutrition 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010050637 Skin tightness Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 241001466451 Stramenopiles Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- 241000482316 Tetraselmis apiculata Species 0.000 description 1
- 241000764162 Tetraselmis astigmatica Species 0.000 description 1
- 241000894100 Tetraselmis chuii Species 0.000 description 1
- 241001478733 Tetraselmis convolutae Species 0.000 description 1
- 241001378732 Tetraselmis cordiformis Species 0.000 description 1
- 241001206227 Tetraselmis gracilis Species 0.000 description 1
- 241000482317 Tetraselmis inconspicua Species 0.000 description 1
- 241000134057 Tetraselmis marina Species 0.000 description 1
- 241000042515 Tetraselmis rubens Species 0.000 description 1
- 241000196320 Tetraselmis striata Species 0.000 description 1
- 241000405713 Tetraselmis suecica Species 0.000 description 1
- 241001129722 Tetraselmis wettsteinii Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 244000003892 Vaccinium erythrocarpum Species 0.000 description 1
- 241001661641 Verrucosa Species 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 240000007316 Xerochrysum bracteatum Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229920000800 acrylic rubber Polymers 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000016720 allyl isothiocyanate Nutrition 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 150000001453 anthocyanidins Chemical class 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical class C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 229940111759 benzophenone-2 Drugs 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- HHBIQTAAJCSNCD-UHFFFAOYSA-N bis(2,4-dihydroxyphenyl)methanone;bis(2-hydroxy-4-methoxyphenyl)methanone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=C(O)C=C1O.OC1=CC(OC)=CC=C1C(=O)C1=CC=C(OC)C=C1O HHBIQTAAJCSNCD-UHFFFAOYSA-N 0.000 description 1
- SODJJEXAWOSSON-UHFFFAOYSA-N bis(2-hydroxy-4-methoxyphenyl)methanone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=C(OC)C=C1O SODJJEXAWOSSON-UHFFFAOYSA-N 0.000 description 1
- RFVHVYKVRGKLNK-UHFFFAOYSA-N bis(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CC=C(OC)C=C1 RFVHVYKVRGKLNK-UHFFFAOYSA-N 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229960004008 butamben picrate Drugs 0.000 description 1
- ATAGSVCDFKGYPE-UHFFFAOYSA-N butamben picrate Chemical compound CCCCOC(=O)C1=CC=C(N)C=C1.CCCCOC(=O)C1=CC=C(N)C=C1.OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O ATAGSVCDFKGYPE-UHFFFAOYSA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229940051246 camellia oleifera leaf extract Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 239000001722 capsicum frutescens oleoresin Substances 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 229940050948 capsicum oleoresin Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229940059958 centella asiatica extract Drugs 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- DRVWBEJJZZTIGJ-UHFFFAOYSA-N cerium(3+);oxygen(2-) Chemical class [O-2].[O-2].[O-2].[Ce+3].[Ce+3] DRVWBEJJZZTIGJ-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 229940099898 chlorophyllin Drugs 0.000 description 1
- 235000019805 chlorophyllin Nutrition 0.000 description 1
- 229960003993 chlorphenesin Drugs 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000036569 collagen breakdown Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940108925 copper gluconate Drugs 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical class C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical class C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
- 229940045574 dibucaine hydrochloride Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- GMSCBRSQMRDRCD-UHFFFAOYSA-N dodecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)=C GMSCBRSQMRDRCD-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- KNZADIMHVBBPOA-UHFFFAOYSA-N dyclonine hydrochloride Chemical compound [Cl-].C1=CC(OCCCC)=CC=C1C(=O)CC[NH+]1CCCCC1 KNZADIMHVBBPOA-UHFFFAOYSA-N 0.000 description 1
- 229960003462 dyclonine hydrochloride Drugs 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960004697 enzacamene Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 125000000816 ethylene group Chemical class [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229940082009 galactoarabinan Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000019717 geranium oil Nutrition 0.000 description 1
- 239000010648 geranium oil Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000003316 glycosidase inhibitor Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- PMMXXYHTOMKOAZ-UHFFFAOYSA-N hexadecyl 7-methyloctanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCC(C)C PMMXXYHTOMKOAZ-UHFFFAOYSA-N 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 229960004931 histamine dihydrochloride Drugs 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000008633 juniper tar Substances 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960001669 kinetin Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 229960001983 magnesium aspartate Drugs 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- SOXAGEOHPCXXIO-DVOMOZLQSA-N menthyl anthranilate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C1=CC=CC=C1N SOXAGEOHPCXXIO-DVOMOZLQSA-N 0.000 description 1
- 229960002248 meradimate Drugs 0.000 description 1
- 229940100630 metacresol Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 229960001238 methylnicotinate Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- MJVGBKJNTFCUJM-UHFFFAOYSA-N mexenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=C(C)C=C1 MJVGBKJNTFCUJM-UHFFFAOYSA-N 0.000 description 1
- 239000011806 microball Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 1
- 229960003921 octisalate Drugs 0.000 description 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940031709 peg-30-dipolyhydroxystearate Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- LKTOWUZQHJSGAK-UHFFFAOYSA-N phenol;4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical compound OC1=CC=CC=C1.C1CC2(C)C(=O)CC1C2(C)C LKTOWUZQHJSGAK-UHFFFAOYSA-N 0.000 description 1
- 229940031827 phenolate sodium Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 229940074122 phyllanthus emblica fruit extract Drugs 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229950001046 piroctone Drugs 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 229940019974 pramoxine hydrochloride Drugs 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 229960000286 proflavine Drugs 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 229960005038 quinisocaine Drugs 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229940002683 retin-a Drugs 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000010018 saw palmetto extract Substances 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- NESLWCLHZZISNB-UHFFFAOYSA-M sodium phenolate Chemical compound [Na+].[O-]C1=CC=CC=C1 NESLWCLHZZISNB-UHFFFAOYSA-M 0.000 description 1
- KJCLYACXIWMFCC-UHFFFAOYSA-M sodium;5-benzoyl-4-hydroxy-2-methoxybenzenesulfonate Chemical compound [Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 KJCLYACXIWMFCC-UHFFFAOYSA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- 235000001508 sulfur Nutrition 0.000 description 1
- 229960000368 sulisobenzone Drugs 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- 229960002494 tetracaine hydrochloride Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940042129 topical gel Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- 229960000732 tripelennamine hydrochloride Drugs 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002569 water oil cream Substances 0.000 description 1
- 229940124024 weight reducing agent Drugs 0.000 description 1
- 235000020334 white tea Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9722—Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9761—Cupressaceae [Cypress family], e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- This invention provides, inter alia, a biologic sunscreen composition comprising whole mount Algae in a topical formulation.
- the compositions provide for excellent balance between UV-A and UV-B absorbance/scattering and protection.
- UV radiation such as from the sun
- UV radiation can lead to the formation of light dermatoses and erythemas, as well as increase the risk of skin cancers, such as melanoma, and accelerate skin aging, such as loss of skin elasticity and wrinkling.
- Light having wavelengths in both the UV-A range (from about 320 to 400 nm) and the UV-B range (from about 280 to about 320 nm) can cause such skin damage, and, thus, sunscreen compositions should preferably comprise both UV-A and UV-B absorbers/reflectors (UV sunscreens).
- UV-B absorbers are available for sunscreening purposes, however there are far fewer choices available for UV-A filtration, particularly in the longer wavelength regions of UV-A (340-400 nm).
- Another confounding issue in the development of high UV-A containing formulations is the fact that the concentration of such UV-A filters that can be included in sunscreen products is heavily regulated and restricted.
- the present invention relates to the finding of an unexpected, advantageous effect of whole mount algae, which, when used in a topical preparation, provides compositions having excellent UV-A and UV-B absorbance capability.
- This invention provides a topical composition comprising non-viable whole cell algae, wherein the non-viable whole cell algae is present at a concentration of 1-20% w/w. In some embodiments, the non- viable whole cell algae is present at a concentration of 5 -15% w/w and in some embodiments, the non-viable whole cell algae is present at a concentration of 2 -10% w/w.
- the non-viable whole cell algae is sized to between 0.5- 15 ⁇ , and in some embodiments, the non-viable whole cell algae is sized to between 0.5 - 10 ⁇ , and in some embodiments, the non-viable whole cell algae is sized to between 0.5 - 6 ⁇ .
- the composition is for cosmetic application and in some embodiments, the composition further comprises a therapeutic agent for skin care.
- the algae is a Tetraselmis, a Nannochloropsis, Isochrysis, or a combination thereof
- the composition is used for sun protection and in some embodiments, the composition is used to prevent skin aging or wrinkling.
- the composition further comprises at least one additional organic or chemical UVA or UVB filter, or combinations thereof.
- the invention provides a method of skin protection said method comprising the step of covering the skin with a homogeneous UVA- UVB protection shield of non- viable whole cell algae.
- the invention provides a method of sun protection against UVB exposure in a subject, said method comprising the step of applying a topical composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of 1-20% w/w to a skin of said subject.
- the invention provides a method of sun protection against UVA exposure in a subject, said method comprising the step of applying a topical composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of 1-20% w/w to a skin of said subject.
- the invention provides a method of protecting a skin against aging or wrinkling in a subject, said method comprising the step of applying a topical composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of 1-20% w/w to a skin susceptible to or suffering from aging or wrinkling in said subject.
- Figure 1 presents a light micrograph of the formation of a thin layer of the algae Tetraselmis.
- Figure 2 presents a light micrograph of the formation of a thin 10 ⁇ of a smeared gel containing 8% Nannochloropsis (X400) .
- Figure 3 presents a light transmiittance curve for a Sun protection product SPF 15 formulation containing 2% Zinc and 7.5% Octhylmethxycinamate:
- Figure 4 presents a light transmittance curve for a Sun protection product SPF 20 formulation
- Figure 5 presents a light transmittance curve for an embodied topical formulation comprising 6% w/w of the algae type Isochrisis.
- Figure 6 presents superimposed light transmittance curves for the Sun protection SPF 15 formulation and that of the embodied formulation comprising 6% w/w Isochrisis algae.
- Figure 7 presents superimposed light transmittance curves for the sun protection SPF 20 formulation containing UVA and UVB filters at 14.5% concentration and that of the embodied topical lotion containing 8% w/w Nannochloropsis algae.
- the invention provides a topical composition, which can serve as a sunscreen.
- Sunscreens serve as a substance, often in the form of a cream or lotion, used to protect the skin from the damaging ultraviolet rays of the sun.
- UV-B radiation It is known that light radiation with wavelengths of between 280 nm and 400 nm makes possible browning of the human epidermis and that rays with wavelengths of between 280 nm and 320 nm, known under the name of UV-B radiation, result in erythemas and cutaneous burns which can be harmful to the development of natural tanning; this UV-B radiation therefore has to be screened out.
- UV-A rays with wavelengths of between 320 and 400 nm which result in browning of the skin, are capable of bringing about a detrimental change in the latter, in particular in the case of sensitive skin or of skin continually exposed to solar radiation.
- UV-A rays are more penetrating than UV-B rays and result in particular in a loss of elasticity of the skin and the appearance of wrinkles, leading to premature aging. They promote the triggering of the erythemal reaction or enhance this reaction in some subjects and can even be the cause of phototoxic or photoallergic reactions. It is therefore desirable also to screen out UV-A radiation.
- Topical application sunscreen formulations are known.
- Sunscreen active are generally classified as organic sun screeners or inorganic sun screeners.
- Organic sun screeners absorb strongly at specific wavelengths and are transparent to visible light.
- some organic sun screeners such as Oxybenzone are known to cause photo allergic reactions.
- Inorganic (Physical) sun screeners such as Titanium dioxide at higher levels leave visible residue referred as whitening of the skin.
- this invention provides a means for harnessing nature to provide a sunscreen for skin, thereby providing more natural sun protection without the need for using topical chemicals, or using much fewer or lower concentrations of chemicals, for protection against sun radiation.
- the invention provides a topical composition comprising nonviable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of about 1-20% w/w.
- the non-viable whole cell algae is present at a concentration of 5 - 15% w/w and in some embodiments, the non-viable whole cell algae is present at a concentration of 2 -10% w/w.
- This invention provides a topical composition comprising non-viable whole cell algae, wherein the non-viable whole cell algae is present at a concentration of 1-20% w/w.
- the non-viable whole cell algae is present at a concentration of 3 -18 % w/w, or in some embodiments, at a concentration of 4 -8% w/w, or in some embodiments, at a concentration of 5 -12% w/w, or in some embodiments, at a concentration of 4 -8% w/w, or in some embodiments, at a concentration of 1 -13% w/w,.
- the invention provides a topical composition comprising non-viable whole cell algae, wherein said non- viable whole cell algae is present at a concentration of about 0.1- 10% w/w. In some embodiments, the invention provides a topical composition comprising nonviable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of about 5-15% w/w. In some embodiments, the invention provides a topical composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of about 10-20% w/w.
- the non-viable whole cell algae is sized to between 0.5- 15 ⁇ , and in some embodiments, the non-viable whole cell algae is sized to between 0.5 - 10 ⁇ , and in some embodiments, the non-viable whole cell algae is sized to between 0.5 - 6 ⁇ .
- anti-sun compositions comprising screening agents which are active in the UV-A region and screening agents which are active in the UV-B region.
- Sunscreen topical composition with particularly advantageous contains screening agents like Butyl Methoxydibenzoylmethane to prevent UV-A, and screening agents which are active in the UV-B region like Ethylhexyl Methoxycinnamate , Ethylhexyl Salicylate and Octocrylene.
- Topical sunscreen spray, cream, lotion, gel and Aerosol or other application mode are usually a combination of Sunscreen filters (Organics and physicals) in an ointment that provide the product to be dispersed equally and easy on the skin, other compound in the ointment are being used to provide water resistance, cosmetic sensory, perfume, chemical stability, preservative and anti contamination properties and other characters to provide best quality topical lotion.
- Sunscreen filters Organics and physicals
- sunscreen filters concentration is elevate with sun protection level (Factors). For example it is estimated that sun protection lotion with SPF 10 and good UVA protection would contain 5-10% sunscreen filters, and similar sun protection at the level of SPF 50 would include above 20% sunscreen filters.
- topical application of sunscreen should be used at a concentration of 2 mg per CM .
- the thickness of such topical application is at the range of 20 ⁇ .
- this topical is an optimal and representing the Sun Protection Factor ( SPF) written on the label, the most common topical skin lotioning is at the range of 10 ⁇ .
- SPF Sun Protection Factor
- Algae are a living particle that absorbed sunlight and convert it to energy source. Algae can be found in most open area in the globe and are highly resistance the UV radiation.
- formulated whole mount algae in topical application are being used to provide UVA and UVB sun protection.
- the invention contemplates that the use of the 0.5-20 ⁇ living particle that absorbs or reflects sun radiation in a cosmetic vehicle with or without sunscreen filters can provide the skin protection against sun radiation (sun protection), with algae serving as an example of such a living particle.
- compositions comprising whole cell algae and other known UVA/UVB filters, which would be expected to be synergistic in their efficacy in the applications described herein.
- the composition is for cosmetic application and in some embodiments, the composition further comprises a therapeutic agent for skin care.
- the alga is Tetraselmis, Isochrysis, Nannochloropsis, or a combination thereof. In some embodiments, the alga is N. gaditana, N. granulate, N. limnetica, N. oceanic, N. oculat , N. salina or a combination thereof.
- the algae is Tetraselmis alacris, Tetraselmis apiculata, Tetraselmis ascus, Tetraselmis astigmatica, Tetraselmis chuii, Tetraselmis convolutae, Tetraselmis cordiformis, Tetraselmis desikacharyi, Tetraselmis gracilis, Tetraselmis hazeni, Tetraselmis impellucida, Tetraselmis inconspicua, Tetraselmis levis, Tetraselmis maculate, Tetraselmis marina, Tetraselmis micropapillata, Tetraselmis rubens, Tetraselmis striata, Tetraselmis suecica, Tetraselmis suecica, Tetraselmis tetrabrachia,Tetraselmis tetratheleTi Tetraselmis verruco
- the alga is Heterokonts, Haptophyta, Cryptomonad, Dinoflagellate or a combination thereof. In some embodiments, the alga is Chlorophyta, Rhodophyta, Glaucophyta, or a combination thereof.
- the alga is Chlorarachniophyte or Euglenid or a combination thereof.
- the alga is Cyanobacteria or blue green algae or a combination thereof.
- the invention provides a composition comprising a non- viable combination of any algae as herein described, or use of a composition comprising the same, for the methods described hereinbelow.
- reference to compositions comprising and use of a non-viable whole cell alga refers, inter alia, to alga which is specifically killed prior to incorporation within the described formulation, for example, via heat, sonication or fixation, or the alga is rendered non-viable upon its formulation within the described compositions, wherein other agents within such composition negatively affect the viability of the alga, such as, for example, preservatives.
- the alga is an isolated, dried preparation, wherein viability of the organism was compromised as part of the drying process.
- the invention contemplates compositions comprising and use of an alga which is viable, yet non-replicative. In some embodiments, the invention contemplates compositions comprising and use of an alga which is viable, yet when applied topically to a subject, such composition/use does not provoke any adverse response in the subject, for example, via provoking no or minimal inflammatory response in the subject. [0051] In some embodiments, the composition is used for sun protection and in some embodiments, the composition is used to prevent skin aging or wrinkling.
- compositions of this invention can be used to prevent, mitigate or abrogate skin aging or skin imperfections both men and women.
- the present disclosure provides an easy to use topical composition and treatment for prevention, mitigation or abrogation of skin aging or skin imperfections in a subject.
- Still another aspect of the invention is represented by a composition as described herein for the prevention, mitigation or abrogation of skin aging or skin imperfections in a subject through the topical application of the various formulations designed for topical application as described herein, optionally combined with at least one skin therapeutic or stimulatory agent comprising lipoxygenase inhibitors, bradykinin inhibitors, prostaglandins and their derivatives, prostaglandin receptor agonists or antagonists, non-prostanoic prostaglandin analogues, vasodilators, cyclosporins and their analogues, antimicrobials, anti- inflammatories, retinoids, 2 0 benzaikonium chloride, benzethonium chloride, phenol, oestradiol, chlorpheniramine maleate, chlorophyllin derivatives, cholesterol, cysteine, methionine, menthol, peppermint oil, calcium pantothenate, panthenol, resorcinol, protein
- compositions of the present invention may be formulated into a lotion, an ointment, a cream, a patch, a spray, a powder, a sachet, a suspension, an emulsion, a solution, or an oil.
- composition of the present invention may be used by directly spreading or spraying it.
- Skin surfaces to which the composition of the present invention is applied include any region of the face, as well as any regions of body, for example, on the neck of the subject.
- the present invention may be used as a lotion, cream, spray, mousse, gel, etc.
- compositions of this invention will further comprise a suitable carrier, which carrier, in some embodiments, is adapted for topical administration to a subject.
- the suitable carrier may comprise of at least one emollient.
- the suitable carrier may be a skin penetrating carrier.
- the skin penetrating carrier may be DMSO, liposomes, lipophilic solvents, lecithin, transcutol, melatonin, nanospheres, nanoshells, cerasomes, and/or rovisomes.
- the skin-penetrating carrier comprises a hollow and solid lipid structure. In another embodiment, the skin-penetrating carrier comprises a nano- structure.
- the suitable carrier is selected from the group consisting of a transdermal patch, lotion, ointment, paste, foam, emulsion, cream, serum, aerosol, spray, roll-on formulation, masque, cleanser, shampoo, conditioner, gel, oil or moisturizer,.
- the suitable carrier can be a lubricating formulation, water-based formulation, silicone-based formulation, petroleum- based formulation, natural-oil based formulation, and/or massage formulation.
- the composition further comprises at least one additional agent.
- the said at least one additional agent can be selected from the group consisting of minerals, antimicrobial agents, antioxidants, antigens, analgesics, anti-inflammatory agents, sebum-reducing agents, hormones, enzymes, peptides, proteins, lipids, retinoids, vitamins, wound recovery agents, botanical extracts, MMP inhibitors, integument and skin-supporting components, or massage oils.
- compositions of the present invention can comprise or consist essentially of the components of the present invention as well as other ingredients described herein.
- the term, "consisting essentially of” refers herein to the fact that the composition or component may include additional ingredients, but only if the additional ingredients do not materially alter the basic and novel characteristics of the claimed compositions or methods.
- compositions when the composition consists essentially of non-viable whole cell algae present as a primary active ingredient therein, at a concentration of between about 0.25 % - about 20.0% w/w, or present as particles ranging in a size of from between about 0.5 to about 10 microns, while other therapeutic agents may be included in the composition, the agent primarily responsible for the improved effect on the skin is the incorporation of the algae, at the concentration or particle size noted.
- Such compositions may further include other additives, and it may be possible to include up to about 10% by weight of materials that could materially alter the basic and novel characteristics of the invention as long as the utility of the algae (as opposed to the degree of utility) is maintained.
- the additional ingredients should be suitable for application to keratinous tissue, that is, when incorporated into the composition they are suitable for use in contact with human keratinous tissue (nails, skin, lips) without undue toxicity, incompatibility, instability, allergic response, and the like within the scope of sound medical judgment.
- CTFA Cosmetic Ingredient Handbook Ninth Edition (2002) describes a wide variety of non-limiting cosmetic and pharmaceutical ingredients, commonly used in the skin care industry, which are suitable for use as additional ingredients in the compositions of the present invention.
- Non-limiting examples of these additional ingredient classes include: healing agents, anti-aging agents, anti-wrinkle agents, moisturizers, antibacterial agents, pesticides, antifongic agents, anti-inflammatory drugs, anti-pruriginous agents, anaesthetic, antiviral agents, keratolytic agents, free radicals scavengers, antiseborrheic, antidandruff agents, anti-acne agents, the agents modulating the differentiation, proliferation or pigmentation of the skin and agents accelerating penetration, cleaning agents, hair conditioning agents, skin conditioning agents, hair styling agents, antidandruff agents, hair growth promoters, Fragrances, sunscreen and/or sunblock compounds, pigments, film formers, hair colors, make-up agents, detergents, pharmaceutical drugs, thickening agents, emulsifiers, humectants, emollients, antiseptic agents, deodorant actives, dermatologically acceptable carriers, surfactants, abrasives, absorbents, aesthetic components such as fragrances, colorings
- binders biological additives, enzymes, enzymatic inhibitors, enzyme-inducing agents, coenzymes, plant extracts, ceramides, peptides, buffering agents, bulking agents, chelating agents, chemical additives, colorants, cosmetic astringents, cosmetic biocides, denaturants, drug astringents, external analgesics, film formers or materials, e.g., polymers, for aiding the film- forming properties and substantivity of the composition (e.g., copolymer of eicosene and vinyl pyrrolidone), quaternary derivatives, agents increasing the substantivity, opacifying
- compositions of the present invention generally contain at least one additional ingredient.
- the compositions of the present invention may contain a plurality of additional ingredients as well.
- the composition further comprises an antimicrobial agent selected from the group consisting of triclosan, povidone, iodine, proflavine, honey, hydrogen peroxide, clotrimazole, parabens, phenoxyethanol, diazolidinyl urea, chlorphenesin or sulfur.
- the composition further comprises an antioxidant selected from the group consisting of beta glucan, curcumin, carnosine, polyphenolics, superoxide dismutase (SOD), catalase, glutathione peroxidase, oligomeric proanthocyanidins, bioflavonoids, oligomeric procyanidolic complexes, leuco anthocyanin, anthocyanidin, alpha-Iipoic acid, coenzyme Q-l 0, selenium, vitamin E, vitamin C, lycopene, tocotrienols, or glutathione.
- an antioxidant selected from the group consisting of beta glucan, curcumin, carnosine, polyphenolics, superoxide dismutase (SOD), catalase, glutathione peroxidase, oligomeric proanthocyanidins, bioflavonoids, oligomeric procyanidolic complexes, leuco anthocyanin, anthocyanidin
- the composition further comprises an analgesic comprising an amine-containing local anesthetic.
- the composition further comprises an antihistamine analgesic.
- the composition further comprises an analgesic selected from the group consisting of paracetamol, NSAIDs, benzocaine, butamben picrate, dibucaine, dibucaine hydrochloride, dimethisoquin hydrochloride, dyclonine hydrochloride, lidocaine, lidocaine hydrochloride, pramoxine hydrochloride, tetracaine, tetracaine hydrochloride, alcohols and ketones, benzyl alcohol, camphor, combinations of camphor and phenol, camphorated metacresol, juniper tar, menthol, phenol, phenolate sodium, resorcinol, antihistamines, diphenylhydramine hydrochloride, tripelennamine hydrochloride, hydrocor
- composition according to the present invention further comprises anti-inflammatory agents selected from the group consisting of hyssop, licorice extract, aloe, salicylic acid, allantaoin, bisabolol, or fumaric acid.
- anti-inflammatory agents selected from the group consisting of hyssop, licorice extract, aloe, salicylic acid, allantaoin, bisabolol, or fumaric acid.
- the composition further comprises a lipid selected from the group consisting of glycerides, phospholipids, phosphatidylcholine, or lecithin.
- the composition further comprises a retinoid selected from the group consisting of tretinoin, retinol, rose hips, or 9-cis retinoic acid.
- a retinoid selected from the group consisting of tretinoin, retinol, rose hips, or 9-cis retinoic acid.
- some particular embodiments may further comprise vitamins wherein the said vitamin is selected from the group consisting of vitamin A, Bl, B2, B3, B5, B6, B7, B9, B12, C, Ester-C, D, E, F, or K.
- Other embodiments may comprise vitamin containing compounds such as rose hips.
- wound recovery agents selected from the group consisting of allantoin, beta glucan, geranium extract, azelaic acid, curcumin, fumaric acid, gamma linolenic acid, farsenol, or squalene.
- the present invention provides for compositions comprising MMP inhibitors selected from the group consisting of minimal-domain MMPs, simple hemopexin domain-containing MMPs, gelatin-binding MMPs, furin-activated MMPs, and vitronectin-like insert MMPs, type I transmembrane MMPs, glycosyl-phosphatidyl inosital (GPI)-linked MMPs, or type II transmembrane MMPs.
- MMP inhibitors selected from the group consisting of minimal-domain MMPs, simple hemopexin domain-containing MMPs, gelatin-binding MMPs, furin-activated MMPs, and vitronectin-like insert MMPs, type I transmembrane MMPs, glycosyl-phosphatidyl inosital (GPI)-linked MMPs, or type II transmembrane MMPs.
- compositions comprising polysaccharides such as beta glucan or dextran.
- some embodiments comprise integument and integument and skin- supporting components selected from the group consisting of vitamin K, borage oil, flax seed, cod liver oil, black currant, alpha and beta hydroxy acids, grape seed, pycnogenol, rose hips, sunscreens, tea tree oil, acetyl glucosamine algae, collagen, elastin, copper PCA, dead sea minerals, glycerin, hormone creams, human growth factor, kinetin, lanolin, mineral oil, olive oil, oxygen, perflurodecalin (Rejuvenox), soy lecithin phospholipids, hydrogen peroxide, triclosan, salicylic acid, papain, aloe vera, lavender oil, geranium oil, chamomile, calendula officinalis, squalane, magnesium oxide crystals, macademia nut oil, galactoarabinan, magnesium aluminum silicate, sweet almond oil, sesame oil, palmitoyl- pent
- the composition comprises at least one additional agent selected from the group consisting of base components, surfactants, thickening agents, gelling agents, stabilizing agents, emulsifying agents, dispersing agents, suspending agents, humectants, emollients, acidic or alkaline substances, buffering agents, anti-crystalline agents, lubricating agents, coloring agents, perfumes, excipients, foaming agents, diluents, fillers, binding agents, or preservatives.
- additional agent selected from the group consisting of base components, surfactants, thickening agents, gelling agents, stabilizing agents, emulsifying agents, dispersing agents, suspending agents, humectants, emollients, acidic or alkaline substances, buffering agents, anti-crystalline agents, lubricating agents, coloring agents, perfumes, excipients, foaming agents, diluents, fillers, binding agents, or preservatives.
- the described components of the composition are encapsulated by a protective membrane.
- the protective membrane can be a liposome, nanosphere, rovisome, cerasome, or nanoshell.
- the protective membrane encapsulates a portion of the components.
- a protective liposomal membrane encapsulates a portion of the components.
- composition pH preferably ranges from about 5 to about 8, more preferably from about 6 to about 7. It can be adjusted by adding acid, such as, for example, hydrochloric acid or citric acid.
- compositions according to the invention may be in all the galenic forms conventionally used for a topical application, including in the form of aqueous, hydroalcoholic or oily solutions, oil-in-water emulsions (O/W), or water-in-oil emulsions (W/O), or multiple emulsions, such as water-in-oil-in-water emulsions (W/O/W) of aqueous or oily gels, of liquid anhydrous products, either pasty or solid, or dispersions of a greasy phase in an aqueous phase in the presence of spherules, such as spherules being adapted to be polymeric nanoparticles such as nanospheres or nanocapsules, or lipidic vesicles, either of a ionic and/or non ionic type.
- Such compositions are prepared according to the usual methods.
- compositions used according to the invention can be more or less fluid and show the aspect of a white or colored cream, a balm, a milk, a lotion, a serum, a paste or a foam.
- They may possibly be applied onto the skin in the form of an aerosol. They may also be in a solid form, such as a stick.
- compositions of this invention will, in some embodiments, comprise pharmaceutically acceptable and/or suitable carriers
- a "pharmaceutically acceptable,” “acceptable,” and/or “suitable” carrier includes any and/or all solvents, dispersion media, coatings, isotonic, and/or absorption delaying agents and/or the like.
- the phrases “pharmaceutically,” “pharmacologically,” “suitable,” and/or “acceptable” refer to materials, substances, or compositions that do not produce an adverse, allergic or other untoward reaction when administered to a subject. The selection and use of such materials may be readily determined by one of skill in the art.
- Carriers can optionally include one or more components which can be biologically active or inactive.
- optional inactive components include base components (e.g., water, propylene glycol, glycerol, polyethylene glycols, silicones, and/or an oil, such as liquid paraffin, vegetable oil, peanut oil, castor oil, and cocoa butter), surfactants, thickening agents (e.g., aluminum stearate and hydrogen lanolin), gelling agents, stabilizing agents, emulsifying agents, dispersing agents, suspending agents, humectants, emollients, acidic or alkaline substances, buffering agents, anti-crystalline agents, lubricating agents, coloring agents, perfumes, excipients (e.g., starch, tragacanth, and cellulose derivatives), foaming agents, diluents, fillers, binding agents, and preservatives (e.g., methyl paraben, propyl paraben, methylchloroisothiazolinone, and methylisothiazolinone).
- Suitable carriers also include water-
- the carrier may comprise capsules suitable for depositing actives, fragrances, color, glitter etc. onto the skin and integument.
- Capsules suitable for deposition include, for example, capsules made from mannitol, lactose cellulose, and hydroypropylmethylcellulose. Suitable capsules are, for example, marketed using the Unispheres process of Inducehm, Dubendorf, Switzerland.
- the present invention also provides for skin-penetrating or skin- permeating carriers.
- skin-penetrating or skin- permeating carriers include, for example, DMSO, liposomes, lipophilic solvents, lecithin, transcutol, nanospheres, nanoshells, and rovisomes.
- the cosmetic or dermatological composition of the invention may also contain usual adjuvants in the cosmetic or dermatological field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic actives, preservatives, antioxidants, solvents, perfumes, fillers, lipophilic or hydrophilic sun filters, bactericides, odour absorbents, colorants, salts and polymers.
- adjuvants in the cosmetic or dermatological field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic actives, preservatives, antioxidants, solvents, perfumes, fillers, lipophilic or hydrophilic sun filters, bactericides, odour absorbents, colorants, salts and polymers.
- the amounts of these various adjuvants are those conventionally used in the involved field and, for example, range from about 0.01 to about 30% of the total weight of the composition.
- Such adjuvants according to their nature, can be introduced into the greasy phase, in the aqueous phase and/
- Fillers adapted to be used in the composition of the invention may include, for example, besides pigments, fibres; talcum; polyamide particles, more particularly those sold under trademark ORGASOLTM by Atochem company; polyethylene powders; acrylic copolymer based microspheres, such as those made of a copolymer of ethylene glycol dimethacrylate and lauryl methacrylate, sold by Dow Corning company under trademark POLYTRAPTM; expanded powders such as hollow microspheres and, more particularly, microspheres sold under trademark
- Such fillers may be present in amounts ranging from 0 to 20% wt, and preferably, from 1 to 10% wt based on the total weight of the composition.
- Hydrophilic gelling agents may include, for example, carboxyvinyl polymers such as products sold under trademark CARBOPOLTM (CTFA name: carbomer) by Goodrich company, acrylic copolymers such as acrylate/alkylacrylate copolymers, polyacrylamides, and, for example, the mixture sold under tradename SEPIGELTM, 2-acrylamido 2-methylpropane sulfonic acid polymers and copolymers, either cross-linked or not, and neutralized or not, such as the product sold by Hoechst company under trademark "Hostacerin AMPS” (CTFA name: ammonium polyacryl-dimethyltauramide), polysaccharides such as cellulose derivatives, and more particularly hydroxyethylcellulose, natural gums such as xanthane gum, and clays.
- Lipophilic gelling agents may include the modified clays such as bentones, fatty acid metal salts, polymers and copolymers of vinyl methyl ether and maleic anhydride such as products sold under trademarks STABILEZETM by ISP company (CTFA name: PVM/MA Decadiene Crosspolymer), and polyethylenes.
- modified clays such as bentones, fatty acid metal salts, polymers and copolymers of vinyl methyl ether and maleic anhydride such as products sold under trademarks STABILEZETM by ISP company (CTFA name: PVM/MA Decadiene Crosspolymer), and polyethylenes.
- Actives may include in particular all the actives known for their activity on skin ageing, such as keratolytic or prodesquamant agents, for example, a-hydroxy-acids, such as glycolic, lactic, malic, citric, tartaric, mandelic acids and the derivatives thereof; ⁇ -hydroxy-acids such as salicylic acid and the derivatives thereof; a-aceto-acids such as ascorbic acid or vitamin C and the derivatives thereof; ⁇ -ceto-acids; retinoids such as retinol (vitamin A) and the esters thereof (palmitate), retinal, retinoic acid and the derivatives thereof.
- a-hydroxy-acids such as glycolic, lactic, malic, citric, tartaric, mandelic acids and the derivatives thereof
- ⁇ -hydroxy-acids such as salicylic acid and the derivatives thereof
- a-aceto-acids such as ascorbic acid or vitamin C and the derivatives thereof
- Actives may also include vitamins, such as, for example, vitamins B3 or PP (niacinamide), B5 (panthnol), E (tocopherol), Kl and the derivatives of those vitamins and more particularly the esters thereof; anti-free radical agents; sun filters; hydrating agents such as polyols; ceramides; and tensing polymers including organics such as latexes, protein hydrolysates and chitin derivatives; DHEA and the derivatives thereof such as alpha-hydroxy- DHEA; Q10 coenzyme, bleaching and depigmenting agents, such as kojic acid para- aminophenol derivatives, arbutin and the derivatives thereof, and the blends thereof.
- vitamins B3 or PP niacinamide
- B5 panthnol
- E tocopherol
- Kl the derivatives of those vitamins and more particularly the esters thereof
- anti-free radical agents sun filters
- hydrating agents such as polyols; ceramides; and
- the composition further comprises at least one additional organic or chemical UVA or UVB filter, or combinations thereof.
- the composition of the invention may comprise every UVA and UVB filter useful in the cosmetic field.
- UVB filters may include for example: 1 salicylic acid derivatives, more particularly homomenthyl salicylate and octyl salicylate; cinnamic acid derivatives, more particularly 2- ethylhexyl p-methoxycinnamate sold by Givaudan company under trademark PARSOL MCXTM; liquid ( ⁇ '- ⁇ -diphenylacrylate) derivatives, more particularly 2-ethylhexyl a-cyano- ⁇ - ⁇ - diphenylacrylate or octocrylene sold by BASF company under trademark UVINUL N539TM; p- aminobenzoic acid derivatives; 4-methyl benzylidene camphor sold by Merck company under trademark EUSOLEX 6300TM; 2-phenylbenzimi
- UVA filters may include for example: dibenzoylmethane derivatives, more particularly 4-
- a blend of several of such filters may also be used, as well as a blend of UVB and UVA filters, and also blends with physical filters.
- Physical filters may include titanium (amorphous or crystallized titanium dioxide under the rutile or anatase form), zinc, iron, zirconium, cerium oxides or the blends thereof.
- Such metal oxides can be in the form of particles having a micrometric or a nanometric size (nano- pigments). In the nano-pigment form, the particle average sizes range, for example, from about 5 to about 100 nm. Nano-pigments are preferably used in the composition of the invention.
- Filters usually used in the composition of the invention include 2-ethylhexyl p- methoxycinnamate sold under trademark Parsol MCX by Hoffmann-Laroche company, benzene l,4[di(3-methylidenecaampho-10-sulfonic )] acid sold under trademark MEXORYL SXTM by Chimex company, 2-hydroxy-4-methoxy-benzophenone sold under trademark UVINUL M40TM by BASF company, 2-phenylbenzimidazole-5 sulfonic acid sold under trademark EUSOLEX 232TM by Merck company, and the blends thereof.
- the invention provides, in some embodiments, for skin smoothing and skin wrinkle and fine wrinkle attenuation.
- the invention therefore also provides, in some embodiments, a cosmetic treatment method for tensing and smoothing the skin for immediately attenuating the wrinkles and/or the fine wrinkles, characterized in that a composition such as defined here above is applied onto the skin.
- the invention also provides, in some embodiments, a cosmetic treatment method for a wrinkled skin, wherein a composition such as defined hereinabove is applied onto said wrinkled skin in an effective amount for attenuating wrinkles or fine wrinkles, or other signs of skin aging.
- compositions of this invention are formulated as part of a cosmetic product.
- Cosmetics include without limitation, lipstick, mascara, rouge, foundation, blush, eyeliner, lip liner, lip gloss, facial or body powder, sunscreens and blocks, mousse, sprays, whether in the form of creams, lotions, gels, ointments, emulsions, colloids, solutions, suspensions, compacts, solids, pencils, spray-on formulations, brush-on formulations and the like.
- compositions of this invention are useful in the prevention, mitigation or abrogation of skin aging or skin imperfections in a subject.
- Signs of skin aging or skin imperfections include, but are not limited to, all outward visibly and tactilely perceptible manifestations as well as any other macro or micro effects due to skin aging. Such signs may be induced or caused by intrinsic factors or extrinsic factors, e.g., chronological aging and/or environmental damage.
- compositions of this invention for use in prophylactically regulating a skin condition includes delaying, minimizing and/or preventing visible and/or tactile discontinuities in skin (e.g., texture irregularities in the skin which may be detected visually or by feel), including signs of skin aging.
- compositions of this invention for use in therapeutically regulating a skin condition includes ameliorating, e.g., diminishing, minimizing and/or effacing, discontinuities in skin, including signs of skin aging.
- Some of the products produced using the compositions of the present invention and indeed the compositions themselves may be used for prophylactically or therapeutically regulating a skin condition.
- compositions of the present invention are useful for improving skin appearance and/or feel.
- preferred compositions of the present invention are useful for improving the state of the skin that is imperfect or subject to aggression by providing an immediate visual improvement in skin appearance following application of the composition to the skin.
- compositions of the present invention which further contain particulate materials will be most useful for providing the immediate visual improvement.
- compositions of the present invention may also provide additional benefits, including stability, absence of significant (consumer-unacceptable) skin irritation, antiinflammatory activity and good aesthetics.
- the invention provides a method of sun protection against UVB exposure in a subject, said method comprising the step of applying a topical composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of 0.1-20% w/w to a skin of said subject.
- the invention provides a method for the prevention, mitigation or abrogation of skin aging or skin imperfections in a subject, said method comprising topically contacting affected skin in a subject with a composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of 0.1-20% w/w in said composition.
- the skin exposure to the formulation is for a period of time of between at least about 6-8 hours in a 24-hour period. In some embodiments, for best results such exposure is every day. In some embodiments, improvement of the skin's appearance as herein described may be seen in as little as 7 days post-initiation of treatment, and in some embodiments, subjects will see improvement in the reduction of crow's feet, crow's feet wrinkles, overall skin glow, and overall reduction of the appearance of skin wrinkles in under 28 days.
- the invention provides a method of sun protection against UVA exposure in a subject, said method comprising the step of applying a topical composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of 0.1-20% w/w to a skin of said subject.
- the invention provides a method of protecting a skin against aging or wrinkling in a subject, said method comprising the step of applying a topical composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of 0.1-20% w/w to a skin susceptible to or suffering from aging or wrinkling in said subject.
- compositions of the present invention can be administered to any suitable subject including animals, humans, and other organisms. In the context of animals, the compositions of the present invention can also be used for veterinary administration to any suitable animal subject such as, for example, cats, dogs, or horses.
- the term "about” refers to a variance of from 1- 10%, or in another embodiment, 5 - 15%, or in another embodiment, up to 10%, or in another embodiment, up to 25% variance from the indicated values, except where context indicates that the variance should not result in a value exceeding 100%.
- the invention provides, in various embodiments, all variations, combinations, and permutations in which one or more limitations, elements, clauses, descriptive terms, etc., from one or more of the listed claims is introduced into another claim dependent on the same base claim unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise.
- elements are presented as lists, e.g. in Markush group format or the like, it is to be understood that each subgroup of the elements is also disclosed, and any element(s) can be removed from the group.
- Several types of algae include Spirulina, Donaliela, Hematococus, Nannochloropsis and tetraselmis were formulated as a topical GEL, Water in Oil emulsion and Oil in Water emulsion containing 10% w/w non-viable, intact algae.
- Table 1 presents the ingredients and their concentration in a prepared, embodied water in oil emulsion of the invention.
- Table 1 Water in oil emulsion containing 10 % algae.
- Table 2 presents the ingredients and their concentration in a prepared, embodied oil water emulsion of the invention.
- Table 2 Oil in Water formula containing 10% algae:
- Table 3 presents the ingredients and their concentration in a prepared, embodied Gel formulation of the invention.
- each of the formulations were found to be stable, possessing good cosmetic sensory properties and being easy for use in terms of dispensing the formulations on skin.
- other formulations were prepared, whereby Algae were incorporated within the indicated base formulations, containing a combination of UVA and UVB sunscreen Filters [00128]
- Table 4 presents the ingredients and their concentration in a prepared water in oil emulsion, containing 10% algae and UVA and UVB filters.
- Table 4 Water in oil emulsion containing 10 % algae and UVA , UVB Filters.
- Table 5 presents the ingredients and their concentration in a prepared oil emulsion, containing 10% algae and UVA and UVB filters.
- UVA butyl Methoxydibenzoylmethane
- Table 6 presents the ingredients and their concentration in a prepared, gel containing
- Formulations according to Tables 1-6 containing algae were prepared, and tested on human skin for sensorial feeling and cosmetic properties. Due to the small particle (algae) size the sensorial feeling of the above was consistent with that observed upon use of traditional cosmetic topical preparations. It can be concluded that whole mount algae at a size below 20 ⁇ and at a concentration of w/w of up to 20%, do not influence the cosmetics sensory of topical on skin.
- Nannochloropsis Similar tests were conducted with Nannochloropsis. A lotion comprising 8% Nannochloropsis formulated in a cosmetic vehicle were smeared on a glass slide. The Nannochloropsis formulation provided full consistency coverage and exhibited a similar appearance to that observed in Figure 1 ( Figure 2).
- Sunscreen formulations are known to reduce the transmission of UVA and UVB light into skin, which can be monitored, inter alia, via the determination of light transmission by spectrophotometry.
- Sunscreen protection as represented by a sun protection factor (SPF) value to skin burn (Minimal erythematic dose) is typically determined in in vivo testing of human skin irradiated with UVB (280-320 nm only) radiation.
- SPF sun protection factor
- a sun protection of formulation containing 2% Zinc oxide w/w (physical filter for UVA and UVB) and 7.5% of Octhylmethxycinamate has been found to provide an in-vivo value of SPF 15 (Sun Protection Factor) indicating that this sunscreen provides the skin with 15 times its native protection against sun burn.
- FIG 4 presents another example of the usefulness of the spectrophotometric assay for determining sunscreen efficacy.
- a sunscreen of SPF 20 capability having higher UVA protection was assessed.
- the formulation contained: Ethylhexyl Methoxycinnamate 7.5%, Ethylhexyl Salicylate 4%, Octocrylene 1% and sunscreen filter to absorb UVA Butyl Methoxydibenzoylmethane 2%.
- a total of 14.5% of sunscreen filter in the formula was needed to provide the skin protection of 20 times the skin protection against sun burn and to provide some protection against UVA.
- the SPF 20 formula was used to show the transmittance curve for a 10 ⁇ layer thick lotion, as described above, when assayed via spectrophotometry, with transmittance being less, when probing for light transmittance in the UVB range (280-320), as well in the UVA range (320-400nm) .
- Nannochloropsis-containing formulation was effective in preventing UVA transmission (320nm-400nm).
- a method to evaluate the absorbency or the scattering entities of physical or organic filter is the following:
- Nannochloropsis at a concentration of lmg per 100ml demonstrated UVB absorption similar to that observed with known physical and organic sunscreen filters.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to topical compositions comprising non-viable whole cell algae and uses thereof. Methods of protecting the skin and methods of sun protection are disclosed.
Description
BIOLOGIC SUNSCREEN COMPOSITIONS
FIELD OF THE INVENTION:
[001] This invention provides, inter alia, a biologic sunscreen composition comprising whole mount Algae in a topical formulation. The compositions provide for excellent balance between UV-A and UV-B absorbance/scattering and protection.
BACKGROUND OF THE INVENTION
[002] The prolonged exposure to UV radiation, such as from the sun, can lead to the formation of light dermatoses and erythemas, as well as increase the risk of skin cancers, such as melanoma, and accelerate skin aging, such as loss of skin elasticity and wrinkling. Light having wavelengths in both the UV-A range (from about 320 to 400 nm) and the UV-B range (from about 280 to about 320 nm) can cause such skin damage, and, thus, sunscreen compositions should preferably comprise both UV-A and UV-B absorbers/reflectors (UV sunscreens).
[003] Numerous UV-B absorbers are available for sunscreening purposes, however there are far fewer choices available for UV-A filtration, particularly in the longer wavelength regions of UV-A (340-400 nm). Another confounding issue in the development of high UV-A containing formulations is the fact that the concentration of such UV-A filters that can be included in sunscreen products is heavily regulated and restricted.
[004] It would therefore be desirable to have a sunscreen composition that provides both UV-A and UV-B protection, which is highly effective yet less toxic than available formulations, for example, using potentially fewer and more biocompatible ingredients. In particular, if would be desirable to have a sunscreen composition that provides equal UV-A absorbance and UV-B absorbance.
SUMMARY OF THE INVENTION
[005] The present invention relates to the finding of an unexpected, advantageous effect of whole mount algae, which, when used in a topical preparation, provides compositions having excellent UV-A and UV-B absorbance capability.
[006] This invention provides a topical composition comprising non-viable whole cell algae, wherein the non-viable whole cell algae is present at a concentration of 1-20% w/w. In some embodiments, the non- viable whole cell algae is present at a concentration of 5 -15% w/w and in some embodiments, the non-viable whole cell algae is present at a concentration of 2 -10% w/w.
[007] According to this aspect, and in some embodiments, the non-viable whole cell algae is sized to between 0.5- 15 μπι, and in some embodiments, the non-viable whole cell algae is sized to between 0.5 - 10 μπι, and in some embodiments, the non-viable whole cell algae is sized to between 0.5 - 6 μπι.
[008] In some embodiments, the composition is for cosmetic application and in some embodiments, the composition further comprises a therapeutic agent for skin care.
[009] In some embodiments, the algae is a Tetraselmis, a Nannochloropsis, Isochrysis, or a combination thereof
[0010] In some embodiments, the composition is used for sun protection and in some embodiments, the composition is used to prevent skin aging or wrinkling.
[0011] In some embodiments, the composition further comprises at least one additional organic or chemical UVA or UVB filter, or combinations thereof.
[0012] In some embodiments, the invention provides a method of skin protection said method comprising the step of covering the skin with a homogeneous UVA- UVB protection shield of non- viable whole cell algae.
[0013] In some embodiments, the invention provides a method of sun protection against UVB exposure in a subject, said method comprising the step of applying a topical composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of 1-20% w/w to a skin of said subject.
[0014] In some embodiments, the invention provides a method of sun protection against UVA exposure in a subject, said method comprising the step of applying a topical composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of 1-20% w/w to a skin of said subject.
[0015] In some embodiments, the invention provides a method of protecting a skin against aging or wrinkling in a subject, said method comprising the step of applying a topical composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of 1-20% w/w to a skin susceptible to or suffering from aging or wrinkling in said subject.
[0016] All publications, patents, and patent applications mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of a conflict between the specification and an incorporated reference, the specification shall control. Where number ranges are given in this document, endpoints are included within the range. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or subrange within the stated ranges, optionally including or excluding either or both endpoints, in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise. Where a percentage is recited in
reference to a value that intrinsically has units that are whole numbers, any resulting fraction may be rounded to the nearest whole number.
BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 presents a light micrograph of the formation of a thin layer of the algae Tetraselmis.
[0018] Figure 2 presents a light micrograph of the formation of a thin 10 μηι of a smeared gel containing 8% Nannochloropsis (X400) .
[0019] Figure 3 presents a light transmiittance curve for a Sun protection product SPF 15 formulation containing 2% Zinc and 7.5% Octhylmethxycinamate:
[0020] Figure 4 presents a light transmittance curve for a Sun protection product SPF 20 formulation
[0021] Figure 5 presents a light transmittance curve for an embodied topical formulation comprising 6% w/w of the algae type Isochrisis.
[0022] Figure 6 presents superimposed light transmittance curves for the Sun protection SPF 15 formulation and that of the embodied formulation comprising 6% w/w Isochrisis algae.
[0023] Figure 7 presents superimposed light transmittance curves for the sun protection SPF 20 formulation containing UVA and UVB filters at 14.5% concentration and that of the embodied topical lotion containing 8% w/w Nannochloropsis algae.
DETAILED DESCRIPTION OF THE INVENTION
[0024] The invention provides a topical composition, which can serve as a sunscreen. Sunscreens serve as a substance, often in the form of a cream or lotion, used to protect the skin from the damaging ultraviolet rays of the sun.
[0025] It is known that light radiation with wavelengths of between 280 nm and 400 nm makes possible browning of the human epidermis and that rays with wavelengths of between 280 nm and 320 nm, known under the name of UV-B radiation, result in erythemas and cutaneous burns which can be harmful to the development of natural tanning; this UV-B radiation therefore has to be screened out.
[0026] It is also known that UV-A rays with wavelengths of between 320 and 400 nm, which result in browning of the skin, are capable of bringing about a detrimental change in the latter, in particular in the case of sensitive skin or of skin continually exposed to solar radiation. UV-A rays are more penetrating than UV-B rays and result in particular in a loss of elasticity of the skin and the appearance of wrinkles, leading to premature aging. They promote the triggering of the erythemal reaction or enhance this reaction in some subjects and can even be the cause of phototoxic or photoallergic reactions. It is therefore desirable also to screen out UV-A radiation.
[0027] Topical application sunscreen formulations are known. Sunscreen active are generally classified as organic sun screeners or inorganic sun screeners. Organic sun screeners absorb strongly at specific wavelengths and are transparent to visible light. However, some organic sun screeners such as Oxybenzone are known to cause photo allergic reactions. Inorganic (Physical) sun screeners such as Titanium dioxide at higher levels leave visible residue referred as whitening of the skin.
[0028] To overcome these allergic side effects of organic sun screeners and non-aesthetics of inorganic sun screeners, there exist the needs for devising newer formulations that can protect the skin from the harmful effects of the ultraviolet radiations of sun without any undesirable side effects.
[0029] In one aspect, this invention provides a means for harnessing nature to provide a sunscreen for skin, thereby providing more natural sun protection without the need for using topical chemicals, or using much fewer or lower concentrations of chemicals, for protection against sun radiation.
[0030] In some embodiments, the invention provides a topical composition comprising nonviable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of about 1-20% w/w.
[0031] In some embodiments, the non-viable whole cell algae is present at a concentration of 5 - 15% w/w and in some embodiments, the non-viable whole cell algae is present at a concentration of 2 -10% w/w.
[0032] This invention provides a topical composition comprising non-viable whole cell algae, wherein the non-viable whole cell algae is present at a concentration of 1-20% w/w. In some embodiments, the non-viable whole cell algae is present at a concentration of 3 -18 % w/w, or in some embodiments, at a concentration of 4 -8% w/w, or in some embodiments, at a concentration of 5 -12% w/w, or in some embodiments, at a concentration of 4 -8% w/w, or in some embodiments, at a concentration of 1 -13% w/w,. or in some embodiments, at a concentration of 7 -16% w/w, or in some embodiments, at a concentration of 0.1 -20% w/w. In some embodiments, the invention provides a topical composition comprising non-viable whole cell algae, wherein said non- viable whole cell algae is present at a concentration of about 0.1- 10% w/w. In some embodiments, the invention provides a topical composition comprising nonviable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of about 5-15% w/w. In some embodiments, the invention provides a topical composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of about 10-20% w/w.
[0033] According to this aspect, and in some embodiments, the non-viable whole cell algae is sized to between 0.5- 15 μιη, and in some embodiments, the non-viable whole cell algae is sized to between 0.5 - 10 μιη, and in some embodiments, the non-viable whole cell algae is sized to between 0.5 - 6 μηι.
[0034] To provide protection of the skin against UV radiation, use is generally made of anti-sun compositions comprising screening agents which are active in the UV-A region and screening agents which are active in the UV-B region.
[0035] Sunscreen topical composition with particularly advantageous contains screening agents like Butyl Methoxydibenzoylmethane to prevent UV-A, and screening agents which are active in the UV-B region like Ethylhexyl Methoxycinnamate , Ethylhexyl Salicylate and Octocrylene.
[0036] Topical sunscreen spray, cream, lotion, gel and Aerosol or other application mode are usually a combination of Sunscreen filters (Organics and physicals) in an ointment that provide the product to be dispersed equally and easy on the skin, other compound in the ointment are being used to provide water resistance, cosmetic sensory, perfume, chemical stability, preservative and anti contamination properties and other characters to provide best quality topical lotion.
[0037] In sunscreen products the sunscreen filters concentration is elevate with sun protection level (Factors). For example it is estimated that sun protection lotion with SPF 10 and good UVA protection would contain 5-10% sunscreen filters, and similar sun protection at the level of SPF 50 would include above 20% sunscreen filters.
[0038] It is known that topical application of sunscreen should be used at a concentration of 2 mg per CM . The thickness of such topical application is at the range of 20μιη. while this topical is an optimal and representing the Sun Protection Factor ( SPF) written on the label, the most common topical skin lotioning is at the range of 10 μιη.
[0039] Algae are a living particle that absorbed sunlight and convert it to energy source. Algae can be found in most open area in the globe and are highly resistance the UV radiation.
[0040] In this invention, formulated whole mount algae in topical application are being used to provide UVA and UVB sun protection.
[0041] Without being bound by theory, the invention contemplates that the use of the 0.5-20 μπι living particle that absorbs or reflects sun radiation in a cosmetic vehicle with or without sunscreen filters can provide the skin protection against sun radiation (sun protection), with algae serving as an example of such a living particle.
[0042] The invention further contemplates the potential for compositions comprising whole cell algae and other known UVA/UVB filters, which would be expected to be synergistic in their efficacy in the applications described herein.
[0043] In some embodiments, the composition is for cosmetic application and in some embodiments, the composition further comprises a therapeutic agent for skin care.
[0044] In some embodiments, the alga is Tetraselmis, Isochrysis, Nannochloropsis, or a combination thereof. In some embodiments, the alga is N. gaditana, N. granulate, N. limnetica, N. oceanic, N. oculat , N. salina or a combination thereof. In some embodiments, the algae is Tetraselmis alacris, Tetraselmis apiculata, Tetraselmis ascus, Tetraselmis astigmatica, Tetraselmis chuii, Tetraselmis convolutae, Tetraselmis cordiformis, Tetraselmis desikacharyi, Tetraselmis gracilis, Tetraselmis hazeni, Tetraselmis impellucida, Tetraselmis inconspicua, Tetraselmis levis, Tetraselmis maculate, Tetraselmis marina, Tetraselmis micropapillata, Tetraselmis rubens, Tetraselmis striata, Tetraselmis suecica, Tetraselmis tetrabrachia,Tetraselmis tetratheleTi Tetraselmis verrucosa, Tetraselmis wettsteinii, or a combination thereof. In some embodiments, the alga is Chlorella, Nannochloris, Porphyridium or a combination thereof.
[0045] In some embodiments, the alga is Heterokonts, Haptophyta, Cryptomonad, Dinoflagellate or a combination thereof. In some embodiments, the alga is Chlorophyta, Rhodophyta, Glaucophyta, or a combination thereof.
[0046] In some embodiments, the alga is Chlorarachniophyte or Euglenid or a combination thereof.
[0047] In some embodiments, the alga is Cyanobacteria or blue green algae or a combination thereof.
[0048] . In some embodiments, the invention provides a composition comprising a non- viable combination of any algae as herein described, or use of a composition comprising the same, for the methods described hereinbelow.
[0049] In some embodiments, reference to compositions comprising and use of a non-viable whole cell alga refers, inter alia, to alga which is specifically killed prior to incorporation within the described formulation, for example, via heat, sonication or fixation, or the alga is rendered non-viable upon its formulation within the described compositions, wherein other agents within such composition negatively affect the viability of the alga, such as, for example, preservatives. In some embodiments, the alga is an isolated, dried preparation, wherein viability of the organism was compromised as part of the drying process.
[0050] In some embodiments, the invention contemplates compositions comprising and use of an alga which is viable, yet non-replicative. In some embodiments, the invention contemplates compositions comprising and use of an alga which is viable, yet when applied topically to a subject, such composition/use does not provoke any adverse response in the subject, for example, via provoking no or minimal inflammatory response in the subject.
[0051] In some embodiments, the composition is used for sun protection and in some embodiments, the composition is used to prevent skin aging or wrinkling.
[0052] The compositions of this invention can be used to prevent, mitigate or abrogate skin aging or skin imperfections both men and women.
[0053] In one embodiment, the present disclosure provides an easy to use topical composition and treatment for prevention, mitigation or abrogation of skin aging or skin imperfections in a subject.
[0054] Still another aspect of the invention is represented by a composition as described herein for the prevention, mitigation or abrogation of skin aging or skin imperfections in a subject through the topical application of the various formulations designed for topical application as described herein, optionally combined with at least one skin therapeutic or stimulatory agent comprising lipoxygenase inhibitors, bradykinin inhibitors, prostaglandins and their derivatives, prostaglandin receptor agonists or antagonists, non-prostanoic prostaglandin analogues, vasodilators, cyclosporins and their analogues, antimicrobials, anti- inflammatories, retinoids, 2 0 benzaikonium chloride, benzethonium chloride, phenol, oestradiol, chlorpheniramine maleate, chlorophyllin derivatives, cholesterol, cysteine, methionine, menthol, peppermint oil, calcium pantothenate, panthenol, resorcinol, protein kinase C activators, 2 5 glycosidase inhibitors, glycosaminoglycanase inhibitors, pyroglutamic acid esters, hexosaccharidic acid or acylhexosaccharic acid, aryl- substituted 6 ethylenes, N-acylated amino acids, flavonoids, ascomycin derivatives and analogues, histamine antagonists, saponins, proteoglycanase inhibitors, oestrogen agonists and antagonists, pseudopterins, cytokines and growth factor promoters, IL-1 or IL-6 inhibitors, IL-10 promoters, TNF inhibitors, vitamins, benzophenones, hydantoin, octopirox, retinoic acid, antipruritic agents, agents for combating parasites, antifungals, nicotinic acid esters, calcium antagonist agents, hormones, triterpenes, anti-androgen agents, steroidal or non-steroidal inhibitors of 5-reductases, potassium channel agonists, FP receptor agonists, or their mixtures.
[0055] The compositions of the present invention may be formulated into a lotion, an ointment, a cream, a patch, a spray, a powder, a sachet, a suspension, an emulsion, a solution, or an oil.
[0056] Particularly, the composition of the present invention may be used by directly spreading or spraying it. Skin surfaces to which the composition of the present invention is applied include any region of the face, as well as any regions of body, for example, on the neck of the subject.
Therefore, the present invention may be used as a lotion, cream, spray, mousse, gel, etc.
[0057] In another aspect of the invention, the compositions of this invention will further comprise a suitable carrier, which carrier, in some embodiments, is adapted for topical administration to a subject. In another embodiment, the suitable carrier may comprise of at least
one emollient. In further embodiments, the suitable carrier may be a skin penetrating carrier. In preferred embodiments, the skin penetrating carrier may be DMSO, liposomes, lipophilic solvents, lecithin, transcutol, melatonin, nanospheres, nanoshells, cerasomes, and/or rovisomes.
[0058] In other embodiments, the skin-penetrating carrier comprises a hollow and solid lipid structure. In another embodiment, the skin-penetrating carrier comprises a nano- structure.
[0059] In further embodiments, the suitable carrier is selected from the group consisting of a transdermal patch, lotion, ointment, paste, foam, emulsion, cream, serum, aerosol, spray, roll-on formulation, masque, cleanser, shampoo, conditioner, gel, oil or moisturizer,. In additional embodiments, the suitable carrier can be a lubricating formulation, water-based formulation, silicone-based formulation, petroleum- based formulation, natural-oil based formulation, and/or massage formulation.
[0060] In another aspect of the present invention, the composition further comprises at least one additional agent. In some embodiments, the said at least one additional agent can be selected from the group consisting of minerals, antimicrobial agents, antioxidants, antigens, analgesics, anti-inflammatory agents, sebum-reducing agents, hormones, enzymes, peptides, proteins, lipids, retinoids, vitamins, wound recovery agents, botanical extracts, MMP inhibitors, integument and skin-supporting components, or massage oils.
[0061] The compositions of the present invention can comprise or consist essentially of the components of the present invention as well as other ingredients described herein. The term, "consisting essentially of refers herein to the fact that the composition or component may include additional ingredients, but only if the additional ingredients do not materially alter the basic and novel characteristics of the claimed compositions or methods. In some embodiments, when the composition consists essentially of non-viable whole cell algae present as a primary active ingredient therein, at a concentration of between about 0.25 % - about 20.0% w/w, or present as particles ranging in a size of from between about 0.5 to about 10 microns, while other therapeutic agents may be included in the composition, the agent primarily responsible for the improved effect on the skin is the incorporation of the algae, at the concentration or particle size noted. Such compositions may further include other additives, and it may be possible to include up to about 10% by weight of materials that could materially alter the basic and novel characteristics of the invention as long as the utility of the algae (as opposed to the degree of utility) is maintained.
[0062] In one embodiment, where the composition is to be in contact with human or mammalian keratinous tissue, the additional ingredients should be suitable for application to keratinous tissue, that is, when incorporated into the composition they are suitable for use in contact with human keratinous tissue (nails, skin, lips) without undue toxicity, incompatibility, instability,
allergic response, and the like within the scope of sound medical judgment. The CTFA Cosmetic Ingredient Handbook, Ninth Edition (2002) describes a wide variety of non-limiting cosmetic and pharmaceutical ingredients, commonly used in the skin care industry, which are suitable for use as additional ingredients in the compositions of the present invention. Non-limiting examples of these additional ingredient classes include: healing agents, anti-aging agents, anti-wrinkle agents, moisturizers, antibacterial agents, pesticides, antifongic agents, anti-inflammatory drugs, anti-pruriginous agents, anaesthetic, antiviral agents, keratolytic agents, free radicals scavengers, antiseborrheic, antidandruff agents, anti-acne agents, the agents modulating the differentiation, proliferation or pigmentation of the skin and agents accelerating penetration, cleaning agents, hair conditioning agents, skin conditioning agents, hair styling agents, antidandruff agents, hair growth promoters, Fragrances, sunscreen and/or sunblock compounds, pigments, film formers, hair colors, make-up agents, detergents, pharmaceutical drugs, thickening agents, emulsifiers, humectants, emollients, antiseptic agents, deodorant actives, dermatologically acceptable carriers, surfactants, abrasives, absorbents, aesthetic components such as fragrances, colorings/colorants, essential oils, skin sensates, astringents, etc. (e.g., clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate), anti-caking agents, antifoaming agents, antimicrobial agents (e.g., iodopropyl butylcarbamate), antioxidants, binders, biological additives, enzymes, enzymatic inhibitors, enzyme-inducing agents, coenzymes, plant extracts, ceramides, peptides, buffering agents, bulking agents, chelating agents, chemical additives, colorants, cosmetic astringents, cosmetic biocides, denaturants, drug astringents, external analgesics, film formers or materials, e.g., polymers, for aiding the film- forming properties and substantivity of the composition (e.g., copolymer of eicosene and vinyl pyrrolidone), quaternary derivatives, agents increasing the substantivity, opacifying agents, pH adjusters, propellants, reducing agents, sequestrants, skin bleaching and lightening agents (e.g., hydroquinone, kojic acid, ascorbic acid, magnesium ascorbyl phosphate, ascorbyl glucosamine), skin-conditioning agents (e.g., humectants, including miscellaneous and occlusive), skin soothing and/or healing agents and derivatives (e.g., panthenol and derivatives (e.g., ethyl panthenol), aloe vera, pantothenic acid and its derivatives, allantoin, bisabolol, and dipotassium glycyrrhizinate), skin treating agents, thickeners, and vitamins and derivatives thereof, and lignans.
[0063] The compositions of the present invention generally contain at least one additional ingredient. The compositions of the present invention may contain a plurality of additional ingredients as well.
[0064] In some embodiments, the composition further comprises an antimicrobial agent selected from the group consisting of triclosan, povidone, iodine, proflavine, honey, hydrogen peroxide, clotrimazole, parabens, phenoxyethanol, diazolidinyl urea, chlorphenesin or sulfur.
[0065] In other embodiments, the composition further comprises an antioxidant selected from the group consisting of beta glucan, curcumin, carnosine, polyphenolics, superoxide dismutase (SOD), catalase, glutathione peroxidase, oligomeric proanthocyanidins, bioflavonoids, oligomeric procyanidolic complexes, leuco anthocyanin, anthocyanidin, alpha-Iipoic acid, coenzyme Q-l 0, selenium, vitamin E, vitamin C, lycopene, tocotrienols, or glutathione.
[0066] In further embodiments, the composition further comprises an analgesic comprising an amine-containing local anesthetic. In other embodiments, the composition further comprises an antihistamine analgesic. In yet further embodiments, the composition further comprises an analgesic selected from the group consisting of paracetamol, NSAIDs, benzocaine, butamben picrate, dibucaine, dibucaine hydrochloride, dimethisoquin hydrochloride, dyclonine hydrochloride, lidocaine, lidocaine hydrochloride, pramoxine hydrochloride, tetracaine, tetracaine hydrochloride, alcohols and ketones, benzyl alcohol, camphor, combinations of camphor and phenol, camphorated metacresol, juniper tar, menthol, phenol, phenolate sodium, resorcinol, antihistamines, diphenylhydramine hydrochloride, tripelennamine hydrochloride, hydrocortisone preparations, hydrocortisone, hydrocortisone acetate, allyl isothiocyanate, ammonia solutions, methyl salicylate, turpentine oil, histamine dihydrochloride, methyl nicotinate, capsaicin, capsicum, or capsicum oleoresin.
[0067] In some embodiments, the composition according to the present invention further comprises anti-inflammatory agents selected from the group consisting of hyssop, licorice extract, aloe, salicylic acid, allantaoin, bisabolol, or fumaric acid.
[0068] In other embodiments, the composition further comprises a lipid selected from the group consisting of glycerides, phospholipids, phosphatidylcholine, or lecithin.
[0069] Additionally, in some embodiments, the composition further comprises a retinoid selected from the group consisting of tretinoin, retinol, rose hips, or 9-cis retinoic acid.
[0070] Additionally, some particular embodiments may further comprise vitamins wherein the said vitamin is selected from the group consisting of vitamin A, Bl, B2, B3, B5, B6, B7, B9, B12, C, Ester-C, D, E, F, or K. Other embodiments may comprise vitamin containing compounds such as rose hips.
[0071] Further embodiments provide for wound recovery agents selected from the group consisting of allantoin, beta glucan, geranium extract, azelaic acid, curcumin, fumaric acid, gamma linolenic acid, farsenol, or squalene.
[0072] In another embodiment, the present invention provides for compositions comprising MMP inhibitors selected from the group consisting of minimal-domain MMPs, simple hemopexin domain-containing MMPs, gelatin-binding MMPs, furin-activated MMPs, and vitronectin-like insert MMPs, type I transmembrane MMPs, glycosyl-phosphatidyl inosital (GPI)-linked MMPs, or type II transmembrane MMPs.
[0073] In further embodiments, the present invention provides for compositions comprising polysaccharides such as beta glucan or dextran.
[0074] Additionally, some embodiments comprise integument and integument and skin- supporting components selected from the group consisting of vitamin K, borage oil, flax seed, cod liver oil, black currant, alpha and beta hydroxy acids, grape seed, pycnogenol, rose hips, sunscreens, tea tree oil, acetyl glucosamine algae, collagen, elastin, copper PCA, dead sea minerals, glycerin, hormone creams, human growth factor, kinetin, lanolin, mineral oil, olive oil, oxygen, perflurodecalin (Rejuvenox), soy lecithin phospholipids, hydrogen peroxide, triclosan, salicylic acid, papain, aloe vera, lavender oil, geranium oil, chamomile, calendula officinalis, squalane, magnesium oxide crystals, macademia nut oil, galactoarabinan, magnesium aluminum silicate, sweet almond oil, sesame oil, palmitoyl- pentapeptide-3, peptides, benzoic acid, butylene glycol, carbomer, phyllanthus emblica fruit extract, urea, centella asiatica extract, echinacea angustifoila (coneflower) extract, hydrolyzed wheat protein, propylene glycol, bearberry extract, licorice, carnosine, caffeine, cocoa butter, kukui nut, shea butter, mugwort extract (artemesia vulgaris), mango butter, plantago lanceolate leaf extract, xanthan gum, sodium lauryl sulfate, glycolic acid, lactic acid, malic acid, citric acid, aartaric acid, all-trans retinoic acid, allantoin, aloe barbadensis, aminobutyric acid, arbutin, arginine amino acid, azelaic acid, caffeic acid, carnosine, retin-A, ceramides, copper gluconate, superoxide eismutase, curcumin, cystosine, beta glucan, dehydroepiandrosterone, DHEA, dinitrochlorobenzene, dipotassium glycyrrhizinate, hydantoin, DMSO, elastin, Ester-C, bromelian, erythropoietin (EPO), evening primrose oil, farnesol, fumaric acid, GABA (gamma aminobutyric acid/gamma amino-butyric acid), gamma linolenic acid, geranium extract, glutathione, glycyrrhiza glabra glycyrrhetic acid, hesperidin, hyaluronic acid, N6-Furfuryladenine Hormone, kojic acid, Tissue Inhibitors Of Metalloproteinases Matrixyl (TIMPS), vitamin E, vitamin C, flavonoids, palmitoyl panax ginseng root extract, pantothenic acid, pycnogenol scavenger, phosphatidylcholine, resveratrol, retinol, silicone, soy extracts, squalene, sulfur, saw palmetto, tocotrienols, ubiquinone, coenzyme QIO, botox, botulinum toxin, EGF, IGF, calendula officinalis, immortelle, green tea extract, white tea, black tea, glucosamine, algae, yeast, magnesium, magnesium aspartate, glycerin, progesterone, estrogen, lavender, cucumber, DNA, panthenol, zinc gluconate, camellia oleifera leaf extract, or pomegranate.
[0075] In additional embodiments, the composition comprises at least one additional agent selected from the group consisting of base components, surfactants, thickening agents, gelling agents, stabilizing agents, emulsifying agents, dispersing agents, suspending agents, humectants, emollients, acidic or alkaline substances, buffering agents, anti-crystalline agents, lubricating agents, coloring agents, perfumes, excipients, foaming agents, diluents, fillers, binding agents, or preservatives.
[0076] In another aspect of the present invention, the described components of the composition are encapsulated by a protective membrane. In some embodiments, the protective membrane can be a liposome, nanosphere, rovisome, cerasome, or nanoshell. In another embodiment, the protective membrane encapsulates a portion of the components. In further embodiments, a protective liposomal membrane encapsulates a portion of the components.
[0077] The composition pH preferably ranges from about 5 to about 8, more preferably from about 6 to about 7. It can be adjusted by adding acid, such as, for example, hydrochloric acid or citric acid.
[0078] The compositions according to the invention may be in all the galenic forms conventionally used for a topical application, including in the form of aqueous, hydroalcoholic or oily solutions, oil-in-water emulsions (O/W), or water-in-oil emulsions (W/O), or multiple emulsions, such as water-in-oil-in-water emulsions (W/O/W) of aqueous or oily gels, of liquid anhydrous products, either pasty or solid, or dispersions of a greasy phase in an aqueous phase in the presence of spherules, such as spherules being adapted to be polymeric nanoparticles such as nanospheres or nanocapsules, or lipidic vesicles, either of a ionic and/or non ionic type. Such compositions are prepared according to the usual methods.
[0079] Moreover, compositions used according to the invention can be more or less fluid and show the aspect of a white or colored cream, a balm, a milk, a lotion, a serum, a paste or a foam.
[0080] They may possibly be applied onto the skin in the form of an aerosol. They may also be in a solid form, such as a stick.
[0081] The compositions of this invention will, in some embodiments, comprise pharmaceutically acceptable and/or suitable carriers
[0082] In some embodiments, the terms, a "pharmaceutically acceptable," "acceptable," and/or "suitable" carrier includes any and/or all solvents, dispersion media, coatings, isotonic, and/or absorption delaying agents and/or the like. The phrases "pharmaceutically," "pharmacologically," "suitable," and/or "acceptable" refer to materials, substances, or compositions that do not produce an adverse, allergic or other untoward reaction when administered to a subject. The selection and use of such materials may be readily determined by one of skill in the art.
[0083] Carriers can optionally include one or more components which can be biologically active or inactive. Examples of such optional inactive components include base components (e.g., water, propylene glycol, glycerol, polyethylene glycols, silicones, and/or an oil, such as liquid paraffin, vegetable oil, peanut oil, castor oil, and cocoa butter), surfactants, thickening agents (e.g., aluminum stearate and hydrogen lanolin), gelling agents, stabilizing agents, emulsifying agents, dispersing agents, suspending agents, humectants, emollients, acidic or alkaline substances, buffering agents, anti-crystalline agents, lubricating agents, coloring agents, perfumes, excipients (e.g., starch, tragacanth, and cellulose derivatives), foaming agents, diluents, fillers, binding agents, and preservatives (e.g., methyl paraben, propyl paraben, methylchloroisothiazolinone, and methylisothiazolinone). Suitable carriers also include water- based, silicone-based, petroleum-based, natural-oil based, and massage formulations.
[0084] In some embodiments, the carrier may comprise capsules suitable for depositing actives, fragrances, color, glitter etc. onto the skin and integument. Capsules suitable for deposition include, for example, capsules made from mannitol, lactose cellulose, and hydroypropylmethylcellulose. Suitable capsules are, for example, marketed using the Unispheres process of Inducehm, Dubendorf, Switzerland.
[0085] The present invention also provides for skin-penetrating or skin- permeating carriers. These include, for example, DMSO, liposomes, lipophilic solvents, lecithin, transcutol, nanospheres, nanoshells, and rovisomes.
[0086] It is known that the cosmetic or dermatological composition of the invention may also contain usual adjuvants in the cosmetic or dermatological field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic actives, preservatives, antioxidants, solvents, perfumes, fillers, lipophilic or hydrophilic sun filters, bactericides, odour absorbents, colorants, salts and polymers. The amounts of these various adjuvants are those conventionally used in the involved field and, for example, range from about 0.01 to about 30% of the total weight of the composition. Such adjuvants, according to their nature, can be introduced into the greasy phase, in the aqueous phase and/or in the lipidic spherules.
[0087] Fillers adapted to be used in the composition of the invention may include, for example, besides pigments, fibres; talcum; polyamide particles, more particularly those sold under trademark ORGASOL™ by Atochem company; polyethylene powders; acrylic copolymer based microspheres, such as those made of a copolymer of ethylene glycol dimethacrylate and lauryl methacrylate, sold by Dow Corning company under trademark POLYTRAP™; expanded powders such as hollow microspheres and, more particularly, microspheres sold under trademark
EXPANCEL™ by Kemanord Plast company or under trademark MICROPEARL F 80 ED™ by
Matsumoto company; powders from natural organic materials such as maize, wheat or rice
starches, either cross-linked or not, such as the starch powders cross-linked by the octenylsuccinate anhydride sold under trademark DRY-FLO™ by National Starch company; silicone resin microballs such as those sold under trademark TOSPEARL™ by Toshiba Silicone company; and mixtures thereof. Such fillers may be present in amounts ranging from 0 to 20% wt, and preferably, from 1 to 10% wt based on the total weight of the composition.
[0088] Hydrophilic gelling agents may include, for example, carboxyvinyl polymers such as products sold under trademark CARBOPOL™ (CTFA name: carbomer) by Goodrich company, acrylic copolymers such as acrylate/alkylacrylate copolymers, polyacrylamides, and, for example, the mixture sold under tradename SEPIGEL™, 2-acrylamido 2-methylpropane sulfonic acid polymers and copolymers, either cross-linked or not, and neutralized or not, such as the product sold by Hoechst company under trademark "Hostacerin AMPS" (CTFA name: ammonium polyacryl-dimethyltauramide), polysaccharides such as cellulose derivatives, and more particularly hydroxyethylcellulose, natural gums such as xanthane gum, and clays.
[0089] Lipophilic gelling agents may include the modified clays such as bentones, fatty acid metal salts, polymers and copolymers of vinyl methyl ether and maleic anhydride such as products sold under trademarks STABILEZE™ by ISP company (CTFA name: PVM/MA Decadiene Crosspolymer), and polyethylenes.
[0090] Actives may include in particular all the actives known for their activity on skin ageing, such as keratolytic or prodesquamant agents, for example, a-hydroxy-acids, such as glycolic, lactic, malic, citric, tartaric, mandelic acids and the derivatives thereof; β-hydroxy-acids such as salicylic acid and the derivatives thereof; a-aceto-acids such as ascorbic acid or vitamin C and the derivatives thereof; β-ceto-acids; retinoids such as retinol (vitamin A) and the esters thereof (palmitate), retinal, retinoic acid and the derivatives thereof.
[0091] Actives may also include vitamins, such as, for example, vitamins B3 or PP (niacinamide), B5 (panthnol), E (tocopherol), Kl and the derivatives of those vitamins and more particularly the esters thereof; anti-free radical agents; sun filters; hydrating agents such as polyols; ceramides; and tensing polymers including organics such as latexes, protein hydrolysates and chitin derivatives; DHEA and the derivatives thereof such as alpha-hydroxy- DHEA; Q10 coenzyme, bleaching and depigmenting agents, such as kojic acid para- aminophenol derivatives, arbutin and the derivatives thereof, and the blends thereof.
[0092] In some embodiments, the composition further comprises at least one additional organic or chemical UVA or UVB filter, or combinations thereof. In some embodiments, the composition of the invention may comprise every UVA and UVB filter useful in the cosmetic field.
[0093] UVB filters may include for example: 1 salicylic acid derivatives, more particularly homomenthyl salicylate and octyl salicylate; cinnamic acid derivatives, more particularly 2- ethylhexyl p-methoxycinnamate sold by Givaudan company under trademark PARSOL MCX™; liquid (β'-β-diphenylacrylate) derivatives, more particularly 2-ethylhexyl a-cyano-α-β- diphenylacrylate or octocrylene sold by BASF company under trademark UVINUL N539™; p- aminobenzoic acid derivatives; 4-methyl benzylidene camphor sold by Merck company under trademark EUSOLEX 6300™; 2-phenylbenzimidazole 5-sulfonic acid sold under trademark EUSOLEX 232™ by Merck company; 1,3,5-triazine derivatives, more particularly: 2,4,6-tris[p- 2'-ethylhexyl-l'-oxycarbonyl)anilino]-l,3,5-triazine sold by BASF company under trademark UVINUL T150™, and dioctyl butamido triazone sold by Sigma 3V company under trademark UVASORB HEB™, and mixtures of such filters.
[0094] UVA filters may include for example: dibenzoylmethane derivatives, more particularly 4-
(tert-butyl)4'-methoxy dibenzoylmethane sold by Givaudan company under trademark PARSOL
1789™; benzene l,4[di(3-methylidenecampho-10-sulfonic)] acid, possibly under a partially or totally neutralized form, sold under trademark MEXORYL SX™ by Chimex company; benzophenone derivatives, for example: 2,4 dihydroxybenzophenone (benzophenone-1),
2,2',4,4 '-tetra-hydroxybenzophenone (benzophenone-2), 2-hydroxy-4-methoxy-benzophenone
(benzophenone-3) sold under trademark UVINUL M40™ by BASF company, 2-hydroxy-4- methoxy-benzophenone-5 -sulfonic acid (benzophenone-4) as well as the sulfonate form thereof
(benzophenone-5) sold by BASF company under trademark UVINUL MS40™, 2,2'-dihydroxy-
4,4'-dimethoxy-benzophenone (benzophenone-6), 5-chloro-2-hydroxybenzophenone
(benzophenone-7), 2,2'-dihydroxy-4-methoxy-benzophenone (benzophenone-8), the disodium salt of the 2,2'-dihydroxy-4,4-dimethoxy-benzophenone-5,5'-disulfonic diacid (benzophenone-
9), 2-hydroxy-4-methoxy-4'-methyl-benzophenone (benzophnone-10), benzophenone-11, 2- hydroxy-4-(octyloxy)enzophenone (benzophenone-12); silane derivatives or polyorganosiloxanes with a benzophenone group; anthranilates, more particularly the menthyl anthranilate sold by Haarman & Reiner company under trademark NEO HELIOPAN MA™; compounds having per molecule at least two benzoazolyl groups or at least one benzodiazolyl group, more particularly the 14-bis-benzimidazolyl-phenylene-3,3',5,5'-tetrasulfonic acid as well as the salts thereof sold by Haarman & Reimer company; silica-based derivatives of N- substituted benzimidazolyl-benzazoles or benzofuranyl-benzazoles, and in particular: 2-[l-[3-
[1,3,3,3 -tetramethyl- 1 - [(trimethylsilyl)oxy] -disiloxanyl] -propyl] - lH-benzimidazol-2-yl] - benzoxazole, 2- [ 1 - [3- [,3 ,3 ,3 -tetramethyl- 1 - [(trimethylsilyl)oxy] -disiloxanyl] -propyl] - 1H- benzimidazol-2-yl]-benzoxazole, 2-[l-(3-trimethylsilanyl-propyl)-lH-benzimidazol-2-yl]- benzoxazole, 6-methoxyl-l,r-bis(3-trimethylsilanyl-propyl)-lH, l'H-[2,2']bibenzimidazolyl-
benzoxazole, 2-[l-(3-trimethylsilanyl-propyl)-lH-benzimidazol-2-yl]-benzothiazole, which are described in Patent Application EP-A-1 028 120; triazine derivatives, and more particularly, the 2,4-bis{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(4-phenyl)-l,3,5-triazine sold by Ciba Geigy compnay under trademark TINOSORB S™ and the 2,2'-methylenebis-[6-(2H benzotriazol-2-yl)4-(l,l,3,3-tetramethylbutyl)-phenol] sold by Ciba Geigy company under trademark TINOSORB M™; and mixtures thereof.
[0095] A blend of several of such filters may also be used, as well as a blend of UVB and UVA filters, and also blends with physical filters.
[0096] Physical filters may include titanium (amorphous or crystallized titanium dioxide under the rutile or anatase form), zinc, iron, zirconium, cerium oxides or the blends thereof. Such metal oxides can be in the form of particles having a micrometric or a nanometric size (nano- pigments). In the nano-pigment form, the particle average sizes range, for example, from about 5 to about 100 nm. Nano-pigments are preferably used in the composition of the invention.
[0097] Filters usually used in the composition of the invention include 2-ethylhexyl p- methoxycinnamate sold under trademark Parsol MCX by Hoffmann-Laroche company, benzene l,4[di(3-methylidenecaampho-10-sulfonic )] acid sold under trademark MEXORYL SX™ by Chimex company, 2-hydroxy-4-methoxy-benzophenone sold under trademark UVINUL M40™ by BASF company, 2-phenylbenzimidazole-5 sulfonic acid sold under trademark EUSOLEX 232™ by Merck company, and the blends thereof.
[0098] The invention provides, in some embodiments, for skin smoothing and skin wrinkle and fine wrinkle attenuation.
[0099] The invention therefore also provides, in some embodiments, a cosmetic treatment method for tensing and smoothing the skin for immediately attenuating the wrinkles and/or the fine wrinkles, characterized in that a composition such as defined here above is applied onto the skin.
[00100] The invention also provides, in some embodiments, a cosmetic treatment method for a wrinkled skin, wherein a composition such as defined hereinabove is applied onto said wrinkled skin in an effective amount for attenuating wrinkles or fine wrinkles, or other signs of skin aging.
[00101] All terms such as "skin aging," "signs of skin aging," "topical application," and the like are used in the sense in which they are generally and widely used in the art of developing, testing and marketing cosmetic and personal care products. The term "cosmetic composition" or more briefly just "composition" in accordance with the present invention relates to a formulation that can be used for cosmetic purposes or as a basis for delivery of one or more pharmaceutical ingredients. It is also possible that these formulations are used for two or more of these same purposes at one time.
[00102] In some embodiments, the compositions of this invention are formulated as part of a cosmetic product.
[00103] "Cosmetics," as used herein, include without limitation, lipstick, mascara, rouge, foundation, blush, eyeliner, lip liner, lip gloss, facial or body powder, sunscreens and blocks, mousse, sprays, whether in the form of creams, lotions, gels, ointments, emulsions, colloids, solutions, suspensions, compacts, solids, pencils, spray-on formulations, brush-on formulations and the like.
[00104] The compositions of this invention are useful in the prevention, mitigation or abrogation of skin aging or skin imperfections in a subject.
[00105] "Signs of skin aging or skin imperfections" include, but are not limited to, all outward visibly and tactilely perceptible manifestations as well as any other macro or micro effects due to skin aging. Such signs may be induced or caused by intrinsic factors or extrinsic factors, e.g., chronological aging and/or environmental damage. These signs may result from processes which include, but are not limited to, the development of textural discontinuities such as wrinkles and coarse deep wrinkles, skin lines, crevices, bumps, large pores (e.g., associated with adnexal structures such as sweat gland ducts, sebaceous glands, or hair follicles), or unevenness or roughness, loss of skin elasticity (loss and/or inactivation of functional skin elastin), sagging (including puffiness in the eye area and jowls), loss of skin firmness, loss of skin tightness, loss of skin recoil from deformation, discoloration (including undereye rings), blotching, sallowness, hyperpigmented skin regions such as age spots and freckles, keratoses, abnormal differentiation, hyperkeratinization, elastosis, collagen breakdown, and other histological changes in the stratum corneum, dermis, epidermis, the skin vascular system (e.g., telangiectasia or spider vessels), and underlying tissues, especially those proximate to the skin.
[00106] The compositions of this invention for use in prophylactically regulating a skin condition includes delaying, minimizing and/or preventing visible and/or tactile discontinuities in skin (e.g., texture irregularities in the skin which may be detected visually or by feel), including signs of skin aging.
[00107] The compositions of this invention for use in therapeutically regulating a skin condition includes ameliorating, e.g., diminishing, minimizing and/or effacing, discontinuities in skin, including signs of skin aging. Some of the products produced using the compositions of the present invention and indeed the compositions themselves may be used for prophylactically or therapeutically regulating a skin condition.
[00108] Some of the products and compositions of the present invention are useful for improving skin appearance and/or feel. For example, preferred compositions of the present invention are useful for improving the state of the skin that is imperfect or subject to aggression
by providing an immediate visual improvement in skin appearance following application of the composition to the skin. Generally speaking, compositions of the present invention which further contain particulate materials will be most useful for providing the immediate visual improvement.
[00109] Some of the compositions of the present invention may also provide additional benefits, including stability, absence of significant (consumer-unacceptable) skin irritation, antiinflammatory activity and good aesthetics.
[00110] In some embodiments, the invention provides a method of sun protection against UVB exposure in a subject, said method comprising the step of applying a topical composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of 0.1-20% w/w to a skin of said subject.
[00111] In some embodiments, the invention provides a method for the prevention, mitigation or abrogation of skin aging or skin imperfections in a subject, said method comprising topically contacting affected skin in a subject with a composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of 0.1-20% w/w in said composition.
[00112] In some embodiments, the skin exposure to the formulation is for a period of time of between at least about 6-8 hours in a 24-hour period. In some embodiments, for best results such exposure is every day. In some embodiments, improvement of the skin's appearance as herein described may be seen in as little as 7 days post-initiation of treatment, and in some embodiments, subjects will see improvement in the reduction of crow's feet, crow's feet wrinkles, overall skin glow, and overall reduction of the appearance of skin wrinkles in under 28 days.
[00113] In some embodiments, the invention provides a method of sun protection against UVA exposure in a subject, said method comprising the step of applying a topical composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of 0.1-20% w/w to a skin of said subject.
[00114] In some embodiments, the invention provides a method of protecting a skin against aging or wrinkling in a subject, said method comprising the step of applying a topical composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of 0.1-20% w/w to a skin susceptible to or suffering from aging or wrinkling in said subject.
[00115] By "administering" or "application" it is meant that a composition is delivered to the subject in such a way that it can achieve the desired purpose. Compositions of the present invention can be administered to any suitable subject including animals, humans, and other
organisms. In the context of animals, the compositions of the present invention can also be used for veterinary administration to any suitable animal subject such as, for example, cats, dogs, or horses.
[00116] It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as set forth in the appended claims. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed in the scope of the claims.
[00117] In one embodiment, the term "about" refers to a variance of from 1- 10%, or in another embodiment, 5 - 15%, or in another embodiment, up to 10%, or in another embodiment, up to 25% variance from the indicated values, except where context indicates that the variance should not result in a value exceeding 100%.
[00118] In the claims articles such as "a", "an" and "the" mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include "or" or "and/or" between members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention also includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process. Furthermore, it is to be understood that the invention provides, in various embodiments, all variations, combinations, and permutations in which one or more limitations, elements, clauses, descriptive terms, etc., from one or more of the listed claims is introduced into another claim dependent on the same base claim unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise. Where elements are presented as lists, e.g. in Markush group format or the like, it is to be understood that each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements, features, etc., certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements, features, etc. For purposes of simplicity those embodiments have not in every case been specifically set forth in haec verba herein. Certain claims are presented in dependent form for the sake of convenience, but Applicant reserves the right to rewrite any dependent claim in independent format to include the elements or limitations of the independent
claim and any other claim(s) on which such claim depends, and such rewritten claim is to be considered equivalent in all respects to the dependent claim in whatever form it is in (either amended or unamended) prior to being rewritten in independent format.
[00119] Although described with specific examples, the present invention provides for some embodiments comprising variations of the components described above.
[00120] Accordingly, variations, omissions, substitutions, and changes may be made by those skilled in the art without departing from the spirit of the present invention.
[00121] The following examples describe certain embodiments of the invention and should not be construed as limiting the scope of what is encompassed by the invention in any way.
EXAMPLES
EXAMPLE 1:
Preparation of Biologic Sunscreen Formulations
[00122] Several types of algae include Spirulina, Donaliela, Hematococus, Nannochloropsis and tetraselmis were formulated as a topical GEL, Water in Oil emulsion and Oil in Water emulsion containing 10% w/w non-viable, intact algae.
[00123] Table 1 presents the ingredients and their concentration in a prepared, embodied water in oil emulsion of the invention.
Table 1 Water in oil emulsion containing 10 % algae.
[00124] Table 2 presents the ingredients and their concentration in a prepared, embodied oil water emulsion of the invention.
Table 2, Oil in Water formula containing 10% algae:
100
[00125] Table 3 presents the ingredients and their concentration in a prepared, embodied Gel formulation of the invention.
Table 3, Gel with 10% algae
[00126] Each of the formulations were found to be stable, possessing good cosmetic sensory properties and being easy for use in terms of dispensing the formulations on skin.
[00127] In addition, other formulations were prepared, whereby Algae were incorporated within the indicated base formulations, containing a combination of UVA and UVB sunscreen Filters [00128] Table 4 presents the ingredients and their concentration in a prepared water in oil emulsion, containing 10% algae and UVA and UVB filters.
Table 4 Water in oil emulsion containing 10 % algae and UVA , UVB Filters.
100
[00129] Table 5 presents the ingredients and their concentration in a prepared oil emulsion, containing 10% algae and UVA and UVB filters.
Table 5, Oil in Water formula containing 10% algae and UVA , UVB Filters:
Ingredients %
Algae 10
Octocrylene (UVB) 5
Butyl Methoxydibenzoylmethane (UVA) 5
Polyglyceryl-2 Dipolyhydroxystearate 2
PEG-30 Dipolyhydroxystearate 2
Dicaprylyl Ether 4
Octyldodecanol 4
Cetearyl Isononanoate 5
Dicaprylyl Carbonate 6
Cyclomethicone 4
Bees Wax 2
Aqua 66.2
Butylene glycol 3
Magnesium Sulfate 1
Preservative 0.8
100
[00130] Table 6 presents the ingredients and their concentration in a prepared, gel containing
10% algae and UVA and UVB filters.
Table 6, Gel with 10% algae and UVA , UVB Filters.
EXAMPLE 2:
Skin Coverage with the Biologic Sunscreen Formulations
[00131] Formulations according to Tables 1-6 containing algae were prepared, and tested on human skin for sensorial feeling and cosmetic properties. Due to the small particle (algae) size the sensorial feeling of the above was consistent with that observed upon use of traditional cosmetic topical preparations. It can be concluded that whole mount algae at a size below 20μπι
and at a concentration of w/w of up to 20%, do not influence the cosmetics sensory of topical on skin.
[00132] When different commercially available samples of algae were thus formulated, spread over the skin and observed via light microscopy, it was found that algae having a size of less than 20 μπι formed a consistent thin layer that totally covered the skin surface. To demonstrate the consistency of the algae layer, microscopic glass slides were spread with the formulation containing 15% Tetraselamis algae. The glass was covered with lmg lotion/cm to create a 10 μηι thin layer and observed under microscope (Figure 1). As indicated by the microscopic observation, the lotion containing 15% Tetraselamis provided full consistent coverage..
[00133] Similar tests were conducted with Nannochloropsis. A lotion comprising 8% Nannochloropsis formulated in a cosmetic vehicle were smeared on a glass slide. The Nannochloropsis formulation provided full consistency coverage and exhibited a similar appearance to that observed in Figure 1 (Figure 2).
EXAMPLE 3:
Sun Protection with the Biologic Sunscreen Formulations
[00134] Sunscreen formulations are known to reduce the transmission of UVA and UVB light into skin, which can be monitored, inter alia, via the determination of light transmission by spectrophotometry. Sunscreen protection as represented by a sun protection factor (SPF) value to skin burn (Minimal erythematic dose) is typically determined in in vivo testing of human skin irradiated with UVB (280-320 nm only) radiation. For example, a sun protection of formulation containing 2% Zinc oxide w/w (physical filter for UVA and UVB) and 7.5% of Octhylmethxycinamate has been found to provide an in-vivo value of SPF 15 (Sun Protection Factor) indicating that this sunscreen provides the skin with 15 times its native protection against sun burn. The same SPF 15 formula was used in a spectrophotometric assay, which provided a transmittance curve for a 10 μπι layer of applied composition as shown in Figure 3. From Fig 3 it can be observed that the transmission of UVB light (280-320nm) is lowered to about 10%.
[00135] Figure 4, presents another example of the usefulness of the spectrophotometric assay for determining sunscreen efficacy. In this instance, a sunscreen of SPF 20 capability having higher UVA protection was assessed. The formulation contained: Ethylhexyl Methoxycinnamate 7.5%, Ethylhexyl Salicylate 4%, Octocrylene 1% and sunscreen filter to absorb UVA Butyl Methoxydibenzoylmethane 2%. A total of 14.5% of sunscreen filter in the formula was needed to provide the skin protection of 20 times the skin protection against sun burn and to provide some protection against UVA. The SPF 20 formula was used to show the transmittance curve for a 10 μπι layer thick lotion, as described above, when assayed via spectrophotometry, with
transmittance being less, when probing for light transmittance in the UVB range (280-320), as well in the UVA range (320-400nm) .
[00136] When a formulation containing 6% w/w of Isochrisis algae was utilized, the formulation exhibited a profile comparable to that of SPF 15 formulation, in terms of the transmittance values obtained (Fig 5).
[00137] When superimposing the transmission curve for the 2%Zinc and 7.5% OMC formulation (SPF 15 in vivo) with that for the 6% Isochrisis algae (Fig 6) once can observe a comparable efficacy for the 6% algae-containing formulation, in terms of its ability to prevent UV transmission at the same ratio as SPF 15 formula containing 9.5% organic and physical filters.
[00138] Moreover, from figure 6, it was evident that the Isocrisis-containing formulation performed more effectively in terms of preventing transmission in the UVB region (280-320 nra).
[00139] Other types of algae were demonstrated to be effective in terms of reducing UVA transmission, as well (Figure 7). An 8% w/w Nannochloropsis-containing formulation was effective in preventing UVA transmission (320nm-400nm).
[00140] The above-described examples support the finding that a formulation comprising whole mount Algae of a size of less than 15 μπι, when formulated within a cosmetic or topical composition, prevents UV radiation, thereby functioning as sunscreen filters.
EXAMPLE 4:
Biologic sunscreen efficacy is comparable to that of existing filters
A method to evaluate the absorbency or the scattering entities of physical or organic filter is the following:
lmg of the tested material was diluted in 100ml solvent or / H20. The Absorbance of the dilute material at 280-320nm was evaluated and compared to commercially available physical and organic filters. The results are provided in Table 7, hereinbelow:
[00141] Thus administration of Nannochloropsis at a concentration of lmg per 100ml demonstrated UVB absorption similar to that observed with known physical and organic sunscreen filters.
[00142] It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as set forth in the appended claims. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed in the scope of the claims.
Claims
1. A topical composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of 1 -20% w/w.
2. A topical composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of 5-15% w/w.
3. A topical composition comprising non- viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of 2 -10% w/w.
4. The composition of claim 1, wherein said non-viable whole cell algae is sized to between 0.5- 15 μηι.
5. The composition of claim 1, wherein said non-viable whole cell algae is sized to between 0.5 - 10 μπι.
6. The composition of claim 1, wherein said non-viable whole cell algae is sized to between 0.5 - 6 μπι.
7. The composition of claim 1, wherein said composition is for cosmetic application.
8. The composition of claim 7, wherein said composition further comprises a therapeutic agent for skin care.
9. The composition of claim 1, wherein said composition is used for sun protection.
10. The composition of claim 1, wherein said composition is used to prevent skin aging or wrinkling.
11. The composition of claim 1, wherein said composition further comprises at least one additional organic or chemical UVA or UVB filter, or combinations thereof.
12. A method of skin protection said method comprising the step of covering the skin with a homogeneous UVA- UVB protection shield of non-viable whole cell algae.
13. A method of sun protection against UVB exposure in a subject, said method comprising the step of applying a topical composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of 1 -20% w/w to a skin of said subject.
14. A method of sun protection against UVA exposure in a subject, said method comprising the step of applying a topical composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of 1 -20% w/w to a skin of said subject.
15. A method of protecting a skin against aging or wrinkling in a subject, said method comprising the step of applying a topical composition comprising non-viable whole cell algae, wherein said non-viable whole cell algae is present at a concentration of 1 -20% w/w to a skin susceptible to or suffering from aging or wrinkling in said subject.
16. The method of claim 12-15, wherein said non-viable whole cell algae is sized to between 0.5- 15 μηι.
17. The method of claim 12-15, wherein said non-viable whole cell algae is sized to between 0.5 - 10 μιη.
18. The method of claim 12-15, wherein said non-viable whole cell algae is sized to between 0.5 - 6 μηι.
19. The method of claim 12-15, wherein said composition is for cosmetic application.
20. The method of claim 19, wherein said composition further comprises a therapeutic agent for skin care.
21. The method of claim 12-15, wherein said composition is used for sun protection.
22. The method of claim 12-15, wherein said composition is used to prevent skin aging or wrinkling.
23. The method of claim 12-15, wherein said composition further comprises at least one additional organic or chemical UVA or UVB filter, or combinations thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161429205P | 2011-01-03 | 2011-01-03 | |
US61/429,205 | 2011-01-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012093388A2 true WO2012093388A2 (en) | 2012-07-12 |
WO2012093388A3 WO2012093388A3 (en) | 2012-11-01 |
Family
ID=45562385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2011/000974 WO2012093388A2 (en) | 2011-01-03 | 2011-12-28 | Biologic sunscreen compositions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012093388A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3013980A1 (en) * | 2013-12-03 | 2015-06-05 | Biolog Marine Daniel Jouvance Lab De | COMPOSITION BASED ON SEA WATER AND ALGAE EXTRACTS WITH ANTI-AGING SKIN ACTIVITY |
FR3054128A1 (en) * | 2016-07-20 | 2018-01-26 | Societe De Courtage Et De Diffusion - Codif International | COSMETIC COMPOSITIONS COMPRISING BIOMINERAL COMPOUNDS AND CORRESPONDING USES FOR SKIN PROTECTION AGAINST ULTRAVIOLET RADIATION |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1028120A1 (en) | 1999-02-12 | 2000-08-16 | L'oreal | Organosilicon compounds with N-substituted benzimidazole-benzazole or benzofuranyl-benzazole groups, sunscreen compositions containing these compounds and their use |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2971549B2 (en) * | 1990-09-29 | 1999-11-08 | 共栄化学工業株式会社 | Cosmetics |
RU2114632C1 (en) * | 1997-11-27 | 1998-07-10 | Виталий Алексеевич Ириков | Cosmetic agent |
DE10059107A1 (en) * | 1999-12-23 | 2001-06-28 | Henkel Kgaa | Extract of blue alga with high magnesium content, useful for dermatological or cosmetic treatment of skin and hair, stimulates synthesis of adenosine triphosphate and matrix proteins |
DE20008368U1 (en) * | 2000-05-05 | 2000-09-07 | Dötsch-Jutsch, Christel, Dr.rer.nat., 19069 Alt Meteln | Body wraps made from seagrass and healing chalk |
RU2174404C1 (en) * | 2000-11-22 | 2001-10-10 | Ириков Виталий Алексеевич | Antiburning agent |
JP2004331629A (en) * | 2003-05-12 | 2004-11-25 | Unimedical Inc | Skin embrocation agent |
FR2880803B1 (en) * | 2005-01-14 | 2007-03-09 | Secma Biotechnologies Marines | LYOPHILIZATION OF BROWN ALGAE CELLS, PROCESS FOR OBTAINING AND USES |
US8298548B2 (en) * | 2007-07-18 | 2012-10-30 | Solazyme, Inc. | Compositions for improving the health and appearance of skin |
US20080124286A1 (en) * | 2006-11-28 | 2008-05-29 | Lisson Jerold B | Algae supplement and treatment method |
CH696838A5 (en) * | 2007-05-29 | 2007-12-31 | Labo Cosprophar Ag | New cosmetic composition comprises Aosa alga or an extract, useful for sustaining relaxed skin tissue and/or with structural sagging and for relifting parts of the face or body |
FR2928268B1 (en) * | 2008-03-07 | 2011-11-25 | Biolog Marine Daniel Jouvance Lab De | NEW COSMETIC USES OF PYROCYSTIS NOCTILUCA |
WO2010054322A1 (en) * | 2008-11-07 | 2010-05-14 | Solazyme, Inc. | Cosmetic compositions comprising microalgal components |
EP3348255B1 (en) * | 2008-12-05 | 2021-11-10 | Symrise AG | Extracts of tetraselmis sp. for cosmetic and therapeutic purposes |
-
2011
- 2011-12-28 WO PCT/IL2011/000974 patent/WO2012093388A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1028120A1 (en) | 1999-02-12 | 2000-08-16 | L'oreal | Organosilicon compounds with N-substituted benzimidazole-benzazole or benzofuranyl-benzazole groups, sunscreen compositions containing these compounds and their use |
Non-Patent Citations (1)
Title |
---|
"CTFA Cosmetic Ingredient Handbook", 2002 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3013980A1 (en) * | 2013-12-03 | 2015-06-05 | Biolog Marine Daniel Jouvance Lab De | COMPOSITION BASED ON SEA WATER AND ALGAE EXTRACTS WITH ANTI-AGING SKIN ACTIVITY |
FR3054128A1 (en) * | 2016-07-20 | 2018-01-26 | Societe De Courtage Et De Diffusion - Codif International | COSMETIC COMPOSITIONS COMPRISING BIOMINERAL COMPOUNDS AND CORRESPONDING USES FOR SKIN PROTECTION AGAINST ULTRAVIOLET RADIATION |
Also Published As
Publication number | Publication date |
---|---|
WO2012093388A3 (en) | 2012-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2624806B1 (en) | Cosmetic skin care compositions comprising insoluble copper oxide | |
Hameed et al. | Scope of nanotechnology in cosmetics: dermatology and skin care products | |
EP1847247B1 (en) | Compositions comprising a hydroxylated diphenyl-methane derivative | |
TWI465256B (en) | Nanoparticle compositions providing enhanced color for cosmetic formulations | |
US20100055138A1 (en) | Methods and topical formulations comprising colloidal metal for treating or preventing skin conditions | |
US20120128777A1 (en) | Compositions containing lipid micro- or nanoparticles for the enhancement of the dermal action of solid particles | |
KR101327943B1 (en) | Composition based on mineral concentrates derived for precious stones | |
WO2008015249A2 (en) | Cosmetic or pharmaceutical composition containing hyaluronic acid | |
FR2958542A1 (en) | COSMETIC USE OF ORIDONIN AS SLIMMING AGENT | |
EP2544691A2 (en) | Compound, composition, and method for protecting skin from high energy visible light | |
US20160296438A1 (en) | Protective action of lutein against blue light on human skin cell lines | |
EP2114363A2 (en) | Anti-wrinkle cosmetic based on peptides | |
Dias-Ferreira et al. | Skin rejuvenation: Biopolymers applied to UV sunscreens and sheet masks | |
US9744381B2 (en) | Topical compositions and methods for influencing electromagnetic radiation on cutaneous extracellular matrix protein production | |
WO2012093388A2 (en) | Biologic sunscreen compositions | |
WO2020142607A2 (en) | Antioxidant compositions and uses thereof | |
CN117940103A (en) | Topical composition for combating fine lines and wrinkles | |
Lahkar et al. | Smart lipid nanoparticles for cosmetic use | |
WO2020185913A1 (en) | Indole-3-propionic acids and salts and esters thereof for treating skin disorders | |
JP2024537318A (en) | Personal care compositions containing vitamin K2 and hydroxystearic acid | |
CN118354778A (en) | Full optical repair | |
¹Central Tehran Branch | S. Nafisi¹², HI Maibach² | |
US20200281869A1 (en) | Topical compositions containing low molecular weight chitosan derivatives | |
HK1146222B (en) | Nanoparticle compositions providing enhanced color for cosmetic formulations | |
HK1121404B (en) | Composition based on mineral concentrates derived from precious stones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11815727 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11815727 Country of ref document: EP Kind code of ref document: A2 |